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ABSTRACT 
 
Xeno-Free Derivation of Retinal Pigmented Epithelium from  
Human Pluripotent Stem Cells  
 
By 
 
Britney Ocean Pennington 
 
Age-related macular degeneration (AMD) is the leading cause of blindness in the 
elderly and is characterized by the death of the retinal pigmented epithelium (RPE), the cell 
layer located behind the retina. The RPE maintains the health of the primary cells 
responsible for vision, the photoreceptors.  As AMD progresses, the RPE degrades, which 
causes the death of the photoreceptors and a debilitating loss of sight.  Human embryonic 
stem cells (hESCs) can generate a limitless source of RPE for cellular therapies, therefore 
efforts to derive RPE from human embryonic stem cells (hESCs) to graft into AMD patients 
are under development.  This thesis addresses two of the obstacles that hinder the production 
of these therapeutical cells.   First, to manufacture cells for clinical use, it is desirable for 
procedures to be performed under defined conditions free of non-human reagents (xeno-
free).  Therefore, a novel, biomimetic, xeno-free RGD-containing copolymer designed for 
cell culture was investigated and found to support healthy hESC cultures and permit their 
differentiation into functional RPE.  These stem cells and hESC-RPE demonstrate similar 
gene expression, protein localization and phagocytic function as cultures grown on a 
xenogeneic substrate.  The second obstacle pertains to the intense time requirement needed 
  x 
to differentiate hESCs into RPE.  Therefore, we recapitulated the signaling events during 
early embryonic development to expedite the production of hESC-RPE from 1-3 months to 
14 days.  However, this protocol employs full length recombinant growth factors and animal 
derivatives.  These components represent a challenge in employing these cells as therapies 
due to the risk of exposure to non-human immunogens.  Preliminary work to replace the 
xenogeneic substrate and recombinant growth factors with small molecules is presented.  
These pilot studies demonstrate that a xeno-free substrate and dual-Smad inhibition via 
small molecules can rapidly and efficiently differentiate hESCs into a population of cells 
expressing a pigmentation marker.  These studies contribute to the development of defined, 
xeno-free methods for cellular manufacture which can further the translation of stem cell 
therapies to the clinic.  
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I. Introduction 
Britney O. Pennington and Dennis O. Clegg* 
Center for Stem Cell Biology and Engineering, Neuroscience Research Institute, Program in 
Biomolecular Science and Engineering, Department of Molecular Cellular and 
Developmental Biology Department, University of California Santa Barbara, CA 93106.  
 
Chapter 15: Development of a Pluripotent Stem Cell Product in Combination with Substrate 
The Preclinical Development of Pluripotent Stem Cell-Based Therapeutics 
Springer Publishing 2014. 
Abstract    
Age-related macular degeneration (AMD) is the leading cause of blindness in the United 
States of America, which places an immense economic burden on society and severely 
decreases the quality of life in the patients.  Pluripotent stem cells provide an unlimited 
source of retinal pigmented epithelium (RPE) which are being developed as a therapy for 
AMD.  In order to ensure the precise delivery of functional RPE to the diseased site, 
scaffolds that support the cells during transplantation and post-surgery are also being tested. 
This chapter describes recent progress in generating RPE from human embryonic stem cells, 
and the characterization of a novel, biostable scaffold consisting of the polymer parylene-C.  
Stem cell-derived RPE monolayers on scaffolds hold great promise for the treatment of 
AMD and other retinal diseases.  
Abbreviations  Age-Related Macular Degeneration (AMD), chemically induced pluripotent stem cells 
(CiPSCs), hexamethyldisilazane (HMDS), human embryonic stem cells (hESC), induced pluripotent stem cells 
(iPSCs), inner cell mass (ICM), in vitro fertilization (IVF), mesh-supported submicron Parylene- C membrane 
(MSPM), pluripotent stem cell (PSC) Poly(D,L-lactic-co-glycolic acid) (PLGA), poly (ethylene glycol) (PEG), 
reactive ion etching (RIE), retinal pigmented epithelium (RPE), Royal College of Surgeons (RCS), scanning 
electron microscope (SEM), spectral-domain optical coherence tomography (SD-OCT) 
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A. Pluripotent Stem Cell-Derived Retinal Pigmented Epithelium 
Geron Corporation’s clinical trial for treating spinal cord injury in 2009 heralded the 
advent of human embryonic stem cell (hESC)-derived products as therapies for human 
maladies.  In the infancy of this field, the eye is an excellent target organ for novel hESC 
therapies due to its potentially immune privileged state, its excellent endpoint parameters 
with non-invasive imaging techniques and sophisticated surgical protocols already in place.  
Diseases affecting the eye drastically affect the patient’s quality of life and present an 
economic burden to society.  Therefore, developing effective hESC-derived treatments for 
blindness has been an intense topic of research.  All five of the recruiting clinical trials using 
hESC derivatives to treat diseases are targeting ocular pathologies.  This section reviews the 
progress of developing a pluripotent stem cell (PSC) product to treat age-related macular 
degeneration.  
Retinal Pigmented Epithelium & Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is the leading cause of blindness in people 
over 55 years of age and is predicted to cost the United States government at least $845 
million annually as the population ages [1, 2].  Two forms of AMD exist.   The “wet”, 
exudative form is characterized by blood vessel invasion into the retina and accounts for 
about 10% of AMD cases [3].  Vision loss occurs due to the formation of fibrotic scars and 
an accumulation of fluid between the neural retina and its supportive retinal pigmented 
epithelium (RPE) [1].  Currently, only palliative treatments are available for the wet form, 
which includes a regimen of intraocular injections of angiogenesis inhibitors such as 
Lucentis®  and Avastin® and EYLEA®.  The other form of AMD, nonexudative or “dry” 
AMD, afflicts the majority of patients and is characterized by “geographic atrophy” where 
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RPE, photoreceptors and choroid are degenerated or dysfunctional in the macula.  The 
macular area of the retina is responsible for high acuity, central vision, and although it only 
accounts for 4% of the retinal area, it perceives 10% of the visual field [1].  Within the 
macula lies a region of the highest density of color-detecting cone photoreceptor cells in the 
retina.  This fovea is just 2mm in diameter, but its cones allow for 20/20 vision and the 
discernment of fine details [1].  Therefore, vision crucially relies on the photoreceptors in 
the macular region, and these cells are supported and maintained by the underlying RPE. 
The RPE is a polarized epithelial monolayer, meaning the two sides of the 
monolayer perform distinct, specialized functions.  Located just behind the neural retina, the 
apical microvilli of the RPE interact with photoreceptors, while its basal side attaches to the 
basal lamina in Bruch’s membrane, which separates the RPE from the vascular choroid.  
Although it does not directly participate in the transduction of light sensation like the neural 
retina, this epithelial layer performs a myriad of functions essential for vision.  These 
include maintaining the health of the photoreceptors by transporting nutrients from the 
blood, removing old photoreceptor outer segments by phagocytosis, isomerizing all-trans to 
11-cis-retinal to perpetuate the visual cycle, limiting oxidation in the eye, and absorbing 
stray light [1, 4, 5].  
In dry AMD, fatty, proteinacious deposits called drusen accumulate between Bruch’s 
membrane and the RPE monolayer.  Drusen are associated with RPE dysfunction and 
degradation [6].  It is generally accepted that RPE dysfunction and death leads to 
deterioration of the photoreceptors and shriveled choroidal vessels.  Although the molecular 
mechanisms that initiate AMD have not been fully elucidated, both environmental factors 
such as smoking and genetic polymorphisms in complement factors H, B, and 
Apolipoprotein E are associated with AMD [7-10].    
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Since RPE dysfunction primarily causes dry AMD, which accounts for 90% of the 
cases, several efforts have been made to replace the damaged cells with viable RPE to 
rescue visual function [3].  Early efforts to restore healthy RPE to patients with a 
degenerating macular region involved detaching and rotating the retina, or transplanting an 
autologous, peripheral RPE-choroid graft to the affected macular area. Although some 
patients regained light-sensitivity in the region of the graft (demonstrating some modicum of 
proof of concept), overall vision diminished and serious side effects such as retinal 
detachment were observed [11].  Transferring RPE from one region of the eye to the 
diseased site also requires substantial surgical skills and is technically challenging.  
Furthermore, in these autologous graft cases, aged RPE comprise the therapeutic cells, and if 
genetic factors caused the AMD, then the graft will consist of similarly flawed cells [12, 13].  
Generating Stem Cell-Derived RPE for Clinical Applications 
Current efforts to restore healthy RPE to patients use allogenic RPE generated from 
human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), for both 
pluripotent sources can theoretically produce an unlimited supply of RPE for cellular 
therapies [14, 15].  Clinical trials have already been initiated for both hESCs and iPSCs for 
the treatment of AMD [16-18]. 
Pluripotent Stem Cells 
hESCs are characterized as pluripotent cells, meaning they have the powerful ability 
to differentiate into any cell type in the body.  During normal development, hESCs appear as 
the inner cell mass (ICM) region of the blastocyst, which is the embryonic stage five days 
post fertilization.  This hollow cellular cluster contains about one hundred cells, and these 
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blastocysts are routinely generated outside of the body at in vitro fertilization (IVF) clinics 
[19].  Since only a subset of the created blastocysts are selected for implantation, the 
remaining embryos can be cryopreserved for potential future implantations, donated to other 
couples, donated to research after informed consent, or discarded [20].  Once designated for 
research, the hESCs in the ICM of donated blastocysts are harvested, and due to their 
perpetual self-renewing capabilities, can be grown continuously in culture in the lab [21]. 
Embryonic stem cells are not the only pluripotent source for generating RPE, for 
iPSCs are also capable of generating these specialized cells [22]. To accomplish induction of 
pluripotency in a differentiated somatic cell, a cocktail of exogenously applied stem cell 
transcription factors will commandeer the machinery maintaining the host cell’s identity, 
which forcibly reprograms the cell into an embryonic stem cell-like state.  Although 
relatively new to the science world, iPSCs have revolutionized our approach to studying and 
treating diseases. First created with murine cells in 2006 [23] and recapitulated in human 
cells in 2007 by independent labs [24, 25], iPSCs have already earned one of their 
discoverers the Nobel Prize in 2012.  Since iPSCs originate from adult cells, fewer ethical 
and legal concerns hinder their progress towards the clinic.  Additionally, iPSCs will be 
genetically matched to the donor cell type, thus providing the possibility of making patient-
specific stem cells with limited immunogenicity for cellular therapies [26]. 
Early protocols for reprogramming involved virally inserting vectors in the host’s 
genome, which could result in mutagenesis if the insertion disrupted the code for an 
essential gene.  Newer methods use non-integrating vectors, including episomal Epstein Barr 
virus [27] or Sendai Virus [28].  Reprogramming has also been accomplished using mRNAs 
[29] and microRNAs [30]. As the field progresses towards clinical applications, several 
attempts to replace viral integration with small molecules for induction have culminated in a 
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successful virus-free reprogramming of murine somatic cells to pluripotency [31].  Exposing 
mouse embryonic, neonatal and adult fibroblasts to a cocktail of seven small molecules, 
which consisted of a cAMP agonist, GSK and TGF-β inhibitors and chromatin modifiers, 
was sufficient to reprogram the somatic cells into chemically induced pluripotent stem cells 
(CiPSCs) [31]. Reprogramming with small molecules precludes unnecessary tampering with 
the genetic material, which could lead to adverse effects such as activation of oncogenes.   
However, iPSCs are not identical to hESCs and may harbor genetic mutations and 
aging marks incurred by environmental insults on the original somatic cell [32].  
Furthermore, the differentiation capability of iPSC lines is unpredictable [33], even when 
the lines originate from the same cell type.  For example, four RPE lines were 
reprogrammed into iPSCs, but only two displayed preferential re-differentiation back into 
RPE, which was manifested by the expedited appearance of pigmented regions during the 
spontaneous iPSC differentiation [34].  The remaining two lines, however, did not exhibit 
this trend and actually produced fewer pigmented regions than the hESC control [34].  Other 
reports also suggest a disparity in the function of iPSC vs. hESC derived RPE [35].  
Although iPSCs should not be eliminated as a potential source of therapeutic cells, extra 
precaution and characterization should be performed on their derivatives before proceeding 
to the clinic. 
Differentiation of Pluripotent Stem Cells into RPE 
A plethora of protocols describe various ways of generating RPE from pluripotent 
stem cells [15, 16, 22, 33, 36-43].  It has been shown that stem cells grown as adherent 
monolayers or as 3D aggregates in suspension will spontaneously differentiate into a myriad 
of cell types including RPE. Spontaneous differentiation is accomplished by removing 
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molecules such as basic fibroblast growth factor (bFGF) from the stem cell culture 
conditions since these molecules are essential for maintaining hESC pluripotency in vitro.  
The differentiating monolayer or free-floating, spherical embryoid bodies, will then require 
several weeks to months to make patches of pigmented RPE surrounded by other 
differentiating cell types [36, 37, 44].  These pigmented patches may be manually isolated 
from contaminating cell types in order to obtain an enriched population of RPE (Fig. 1). 
 
 
Figure 1. Human embryonic stem cells differentiating into RPE can be manually enriched to 
produce a more pure population of therapeutic cells. Upon removal of bFGF, hESC cultures 
will spontaneously differentiate into a myriad of cell types, including RPE. After about 30 
days in culture, pigmented foci will appear in the culture dishes.  (A) After 100 days in 
culture, large pigmented regions can be observed within the well of the tissue culture vessel 
by the naked eye.  These regions may be manually separated from non-pigmented cells in a 
process termed “enrichment.”  (B) By thirty-five days post-enrichment, a more pure 
population of pigmented hESC-derived RPE can be observed in the tissue culture vessel.  
(C) A brightfield and (D) phase contrast micrograph of an enriched hESC-derived RPE 
culture reveals the typical pigmented, cobblestone morphology with tight junctions between 
cells.  Scale bar = 200µm.  
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Since spontaneous differentiation of stem cells into RPE requires an intense time 
investment, several labs have designed a variety of directed differentiation protocols to 
expedite this derivation.  Furthermore, stimulating the directed differentiation of a particular 
cell type may discourage the growth of contaminating cells, thus increasing the final yield of 
desired cell product.  In these endeavors, natural signaling mechanisms that occur during the 
in vivo development help researchers identify which molecular candidates should be 
exogenously applied to the in vitro stem cells to accelerate their differentiation into RPE.  
The primary events of RPE development in vivo involve neural induction prior to 
gastrulation, specification of the eye field within the embryonic brain, and then maturation 
of specific ocular cells as the eye develops through the optic vesicle and optic cup stages [5, 
45].  
In order to initially guide stem cell differentiation towards a neural fate, as opposed to 
other fates from the mesoderm and endoderm germ lineages, directed differentiation 
protocols have applied neuralizing growth factors such as nicotinamide, Dkk-1, Lefty-A, 
and commercial supplements such as N2 or B27® [33, 40, 41, 43].  Then, additional growth 
factors such as Activin-A, retinoic acid, and TGFβ1 will predispose the neural cells to 
assume an RPE fate upon further differentiation [41]. A report in July 2012 claimed to 
accomplish neuralization in 5 days, and upon addition of Activin-A achieved an RPE yield 
of 95+1% by day 30 [46].  To accomplish this efficient conversion of stem cells to RPE, 
cyst-like aggregates of undifferentiated hESC colonies were embedded in BD Matrigel™ 
hESC-Qualified Matrix, which is an extract rich in extracellular matrix proteins derived 
from the Engelbreth-Holm-Swarm murine sarcoma.  The embedded, three-dimensional 
culture system mimicked the in vivo environment during neural tube formation by 
surrounding the entire cluster of cells with a matrix that supplied contacts for cellular 
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adhesion.  This approach facilitated the rapid attainment of a neural fate and varies from 
other culture methods, which use free-floating spherical aggregates in solution or a 2D 
monolayer.  The embedded neural progenitors however, may produce RPE or neural retinal 
derivatives.  In order to promote an RPE identity, the 3D neural cysts were recovered from 
their Matrigel encasement and plated on a 2D culture system in the presence of Activin-A to 
foster the development of a polarized monolayer.  By day 18, pigmented regions appeared 
followed by the acquisition of the typical cobblestone RPE morphology and expression of 
RPE-specific molecular markers such as Mitf, RPE65 and Bestrophin.  These hESC-derived 
RPE effectively performed phagocytosis on the photoreceptor outer segments when co-
cultured with murine retinal explants.  This differentiation protocol demonstrates the value 
of combining exogenously applied growth factors, embedded 3D conditions and 2D 
monolayers when directing the differentiation of hESCs to RPE [46]. 
  To date, the most rapid directed differentiation protocol generates RPE from 
pluripotent stem cells in 14 days [47].  By combining protocols that efficiently generate 
neural progenitor cells with effective procedures for deriving RPE, 80% of the stem cell 
derivatives at the end of two weeks are positive for PMEL17, a pre-melanosomal protein 
and an RPE marker. [22, 41, 47, 48].  To prime the population of pluripotent stem cells for 
expedited RPE development, the culture first undergoes neural induction to generate an eye 
field precursor population.  This is accomplished by adding nicotinamide and noggin to 
induce a neural fate [41, 49], the canonical wnt inhibitor Dkk-1 which promotes eye field 
development, and IGF-1 which stimulates forebrain and early eye field transcription factor 
expression [5].  Then, the addition of Activin-A and an FGF inhibitor SU5402 effectively 
guides the cells to an RPE fate instead of neural retina.  The RPE generated by the 14th day 
may be enriched and cultured as a monolayer for an additional month.  These cells express 
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RPE markers such as tyrosinase, PEDF and CRALBP, and demonstrate functional 
phagocytosis of rod outer segments.  In addition to rapidly generating RPE, this expedited 
protocol is useful for studying signaling mechanisms during RPE development.  
Furthermore, this group identified a mechanism of partial PARP-1 inhibition as a possible 
explanation of how nicotinamide accelerates the development of RPE from hESCs [41, 47, 
49]. 
However, these directed differentiation protocols use Matrigel™ in their procedures, 
which is an animal derivative.  In order to manufacture cells for clinical use, it is desirable 
for procedures to be performed under defined conditions sans animal products, or xeno-free, 
and many studies are still optimizing the derivation with these parameters [50].  Ideally, 
small molecules could replace recombinant proteins and peptides and xeno-free substrates 
would support pluripotent stem cell maintenance and promote their differentiation to RPE. 
B. Substrates for Stem Cell-Derived RPE 
A biomedical substrate or scaffold aims to provide a supportive, structural surface 
for cells to attach, proliferate, differentiate and perform their normal functions after 
transplantation [51].  Recent results indicate that hESC-RPE monolayers on a substrate 
survive longer than bolus injections of hESC-RPE [52].  The chemical composition and 
physical traits of the substrate significantly influence how the transplanted cells will operate 
in a diseased setting.  Perhaps most importantly, the substrate must support the therapeutic 
cells’ health and function.   This section describes the development of a transplantable 
substrate designed to support the pluripotent stem cell based product, hESC-derived RPE. 
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Types of Substrates 
In order to design an effective substrate for the transplantation of hESC-derived RPE, the 
qualities of the in situ RPE substrate should be considered.  Naturally, the polarized RPE 
monolayer orients its apical side towards the photoreceptors of the neural retina while the 
basolateral side sits upon the supportive, underlying Bruch’s membrane.  This pentalaminar 
Bruch’s membrane consists of an elastin layer sandwiched between two collagen strata, 
which separates the basal membranes of the RPE from the underlying endothelial cells of 
the choriocapillaris blood vessels [53].   In addition to emulating the chemical composition 
during substrate design, the relative thickness of the transplant must also be considered.    
The Bruch’s membrane is 1-4µm thick, and substrates significantly exceeding this 
dimension could distort the contour of the overlying neural retina, and would thus result in a 
deformed visual perception [54].    
Purified proteins or modifications of constituents within the Bruch’s membrane have been 
investigated as candidates for RPE scaffolds.  Gelatin, which is made of single peptide 
chains from the denatured collagen triple helix [55], has been investigated as a substrate 
since it is a derivative of a naturally occurring Bruch’s membrane constituent.  However, 
two layers of RPE opposed to a single monolayer appeared 28 days after transplanting a 
porcine RPE sheet on a gelatin substrate, possibly due to the sheet doubling back on itself 
[56].   Furthermore, employing natural products for substrate fabrication could lead to 
irreproducibility of results due to batch-to-batch variations in the acquisition of these 
proteins.  
Synthetic polymers can be finely tuned to match the physical and chemical properties of 
the transplant’s destination while also providing high reproducibility in large-scale 
manufacturing processes [51].  Both biodegradable and biostable synthetic polymers have 
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been investigated as substrates for RPE transplantation.  The decomposition rate of 
biodegradable scaffolds can be controlled by varying the ratios of the constituents in the 
substrate and the types of bonds connecting them.  Biodegradable scaffolds provide initial 
support to the therapeutic cells during and shortly after the transplantation, and these 
substrates do not leave a residual ectopic product in the eye since they are metabolized over 
time.  However, both the biodegradable polymer and its degradation products must not elicit 
an immune response [51].   
A vast array of synthetic, biodegradable candidate materials have been investigated for 
supporting RPE health and function.  Poly(D,L-lactic-co-glycolic acid) (PLGA) for 
example, is a biodegradable FDA approved poly (α-hydroxy ester) whose properties can be 
tuned by controlling the ratio of the lactide and glycolide constituents  [57, 58].  Certain 
ratios of high molecular weight PLGA can support the adhesion and proliferation of human 
fetal RPE in vitro [57].  Hydrolysis of the ester bond of the two constituents produces 
molecules that are biocompatible and readily metabolized in vivo [51].  However, to our 
knowledge no biodegradable substrates have been used to transplant pluripotent stem cell 
derived RPE into the subretinal space [15].  Conversely, biostable scaffolds would offer 
permanent support to the therapeutic cells, but must not interfere with the natural transport 
of nutrients.     
Parylene-C 
One biostable polymer used in many biomedical applications including transporting RPE 
into the subretinal space is parylene-C, a member of the para-xylylene polymerization 
products [59].  In 1947, Michael Mojzesz Szwarc, a physical chemist at the University of 
Manchester in the aftermath of World War II, noticed that a peculiar coating would 
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accumulate on his equipment when studying the decomposition of gaseous para-xylene [60, 
61].  P-xylene consists of a benzene ring with methyl groups in the para positions, but 
during pyrolysis it converts to p-xylylene, which is kinetically prone to polymerize in the 
solid phase, thus producing the thin, peelable film on Szwarc’s devices [59, 60, 62].   
However in Szwarc’s studies, only 10-15% of the polymerization precursor, p-xylylene was 
produced, which would cause a bottleneck in a larger-scale manufacturing attempt [60, 62].  
In 1966, the production of the polymer was perfected by William Gorham at Union Carbide 
Corporation in New Jersey [59].  Gorham used a di-p-xylylene intermediate, or (2,2)p-
cyclophane, during the production process which yielded 99% of the polymerizing p-
xylylene product, now known as parylene [62].  In 1991, Union Carbide Corporation 
transferred the production of parylenes to Specialty Coating Systems which has since 
founded nine manufacturing locations around the world [63]. 
Today, the commercial synthesis of parylene exclusively uses the Gorham Process, 
which involves 1) the sublimation of di-p-xylylene in a vaporizer, 2) its conversion to the 
gaseous monomer p-xylylene in a pyrolysis chamber and 3) the chemical vapor deposition 
of the gaseous monomer on a given surface at room temperature [59, 62, 64].  Upon 
deposition, the monomer spontaneously polymerizes into poly-p-xylylene, or parylene-N 
[59].  Parylene-N is a linear chain of poly-p-xylylene whose aromatic rings are substituent 
free (Fig. 2).  Functionalizing the benzene ring of the precursors with chlorine atoms 
produces polymer derivatives with varying mechanical, thermal and electrical properties 
known as parylene-C, which possesses one chlorine substituent per aromatic ring, and 
parylene-D, which possesses two (Fig. 2) [59, 65].     
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Figure 2. Structures of parylene variants.   Members in the parylene polymer family have 
distinct physical properties and can be used in various applications.  Parylene-C has been 
implemented in coating electronics and biomedical devices and has been recently engineered 
into ultrathin, semipermeable membranes to serve as a substrate for hESC-derived RPE. 
Initially, the electronics industry capitalized on parylene-C’s low water and gas 
permeability for producing protective coatings for circuit boards.  Also, the chemical vapor 
deposition of parylene results in a conformal coating sans pinholes [59, 64].  Pinholes arise 
from bubbles that are trapped during the deposition process which later burst to create 
defects in the film, thus rendering any underlying circuitry vulnerable [66].  This conformal 
coating property expanded parylene’s application to protecting delicate biomedical circuitry 
implanted into the relatively hostile environment of the body.  Physicians have used 
parylene-C coated pacemakers, stents and electrodes acting as neural prostheses [64, 67]. 
Furthermore, parylene-C is chemically inert and has a Young’s Modulus measure of 
stiffness of 3.2GPa, which confers recalcitrance to tearing [64, 65, 68].  
Engineering Parylene-C into a Biocompatible Substrate 
As a hydrophobic polymer, parylene-C forms a protective barrier that isolates its cargo 
from the body and therefore must be modified in order to support adherent, therapeutic cells 
[64, 65, 69].  Etching parylene-C with oxygen plasma for one to two minutes significantly 
increases its hydrophilicity which enables the polymer to support adherent cells similarly to 
polystyrene, or tissue culture plastic [65, 70].  Additionally, parylene-C may be 
micropatterned into specific structures and stencils by photolithography, thus making it 
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amenable to a range of cellular applications [68, 71, 72].  For example, layered parylene-C 
stencils support patterned in vitro co-cultures of cells, such as stem cells with hepatocytes 
and fibroblasts.  This allows for the regulated study of spatio-temporal effects of 
intercellular contacts between stem cells and their neighbors [68].   
Photolithography is essential in order to use parylene-C as substrate for transplanting 
stem-cell derived RPE into the subretinal space.  As mentioned above, parylene-C is 
impermeable to water, gases and small molecules, which would hinder the RPE function of 
transporting nutrients from the choriocapillaris below the Bruch’s membrane to the 
photoreceptors in the neural retina.  In order to overcome this barrier, ultrathin parylene 
membranes (.15-.80µm) have been designed and fabricated by the Tai Group using a two-
step lithography approach [72, 73].  This method deposits a thicker parylene meshwork 
(6µm) as a base layer to support the subsequent delicate, ultrathin coating (Fig. 3).  Briefly, 
the thick layer of parylene-C coats a silicon foundation treated with hexamethyldisilazane 
(HMDS) (Fig. 3a).  HMDS affects parylene’s adhesion to other chemicals during the 
lithography process [71, 72].  The next two layers include aluminum and a photoresist, a 
substance that confers protection to underlying layers until exposed to light (Fig. 3b).   
Lithography of the photoresist, wet aluminum etching, and reactive ion etching (RIE) of the 
parylene-C bores an array of 20µm diameter cylinders through the underlying strata to the 
silicon base (Fig. 3c,d).  Once this supportive meshwork has been constructed, a final 
application of ultrathin parylene-C and photoresist are applied over the pre-existing layer, 
which results in an array of ultrathin parylene regions supported by the meshwork of thicker 
polymer (Fig. 3e,f,g) [72, 73].  Flipping the ultrathin meshwork after synthesis presents a 
continuous, semi-permeable, biostable substrate to the pluripotent stem cell-derived RPE 
(Fig. 3h).  Ultrathin regions of 0.15-0.50µm thickness have been calculated to permit 
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diffusion of chemicals up to MW ~1,302 to 291 KDa, respectively, which includes most of 
the serum protein [72].  Vitamin A, a nutrient that must pass through the Bruch’s membrane 
to perpetuate the visual cycle, and its carrier have a MW ~75KDa, which suggests ultrathin 
parylene-C meshwork is a viable substrate for emulating the Bruch’s membrane when 
transplanting stem cell-derived RPE [72-75].   
 
 
Figure 3. Photolithography of parylene-C into an ultrathin substrate. (a) A thicker, 6 µm 
layer of parylene-C first coats HMDS treated silicon. (b) A second layer formed by the 
sequential coating of aluminum and photoresist (c) undergoes photolithography and wet-
etching to form a template or mask that protects the underlying parylene-C during the (d) 
reactive ion etching (RIE).  This removes the uncovered parylene-C and results in an array 
of hollow cylinders in the thick parylene layer. e) A second, ultrathin (0.30 µm) layer of 
parylene-C and (f) a photoresist are applied, and a final round of lithography and RIE (g) 
give shape to the final substrate product. (h) The resulting, ultrathin parylene-C membrane is 
removed from the silicon base and inverted to present a continuous, semi-permeable, 
biostable substrate to the pluripotent stem cell-derived RPE. © Biomedical Microdevices 
(2012) 14(4) pp 659-667, "Mesh-supported submicron parylene-C membranes for culturing 
retinal pigment epithelial cells" Lu B, Zhu D, Hinton D, Humayun M, Tai YC, Fig 1.  – with 
kind permission from Springer Science+Business Media.  
 
Having confirmed the ability of parylene-C to permit nutrient transport, it is necessary to 
demonstrate its biocompatibility in the subretinal space.  When compared to poly(imide), 
amorphous aluminum oxide-coated poly(imide), poly(vinyl pyrrolidone) and poly (ethylene 
glycol) (PEG) after transplantation into the subretinal space of Yucatan pigs, parylene-C and 
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PEG did not significantly alter the retinal architecture nor did they instigate abnormal RPE 
behavior for three months [76].    
These studies demonstrate that parylene-C can be fabricated with the proper dimensions 
and characteristics to support cell adhesion, provide appropriate diffusion properties, and to 
not distort the contour of the neural retina nor illicit an immune response.   
C. Combination of Stem Cell-Derived RPE with Substrate for Cellular 
Therapies 
Bringing a cellular therapy from the lab to the clinic requires an astounding 
cooperation among diverse fields.  Collaborations between cell biologists, material 
scientists, physicists, surgeons, and engineers reflect the truly interdisciplinary nature of 
regenerative medicine [77]. Designing a pluripotent stem cell-based product in combination 
with a synthetic substrate for subretinal transplantation to treat AMD exemplifies such 
synergy.  This section discusses the combination of hESC-derived RPE with the synthetic 
parylene-C substrate, surgical strategies to transplant this fabricated product, and the next 
progressive steps in the field.  
Cell-Suspension vs. Adherent Cells on a Substrate for Cellular Therapies for AMD  
An intense topic of interest in the field is the relative efficacy of transplanting 
healthy RPE as a single cell suspension or as a monolayer on a supportive substrate to treat 
AMD.  Both approaches have been investigated, and both are currently undergoing clinical 
trials or pre-clinical animal studies [17, 78-80]. 
Cells in a suspension would be easier to deliver into the eye and would cause less 
trauma during surgery.  The first clinical study to use hESC-derived cells for ocular diseases 
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injected a suspension of hESC-derived RPE into the subretinal space of one dry-AMD 
patient and one Stargardt’s Disease patient and in both cases, observed slight visual 
improvement after four months [17]. However, the degree of degeneration in diseased 
retinas will vary from patient to patient, therefore, it is difficult to extrapolate from this one 
instance the efficacy of injecting an RPE suspension as a viable therapy for the entire AMD 
population.  Cells from a suspension could localize to any retinal area, thus providing a 
randomized, patchy support of photoreceptors [81].  Furthermore, loose cells in a suspension 
may aggregate, precluding the formation of a polarized monolayer and possibly incurring an 
immunological reaction.   
An alternative approach utilizes, solid, transplantable substrates that enable delivery 
of a polarized monolayer to a specific destination while providing support in a diseased 
environment.  Parylene-C is a candidate substrate for transplanting hESC-derived RPE.  Lu 
et al. (2012) have demonstrated that RPE derived from the H9 hESC line can adhere and 
grow into a confluent monolayer with characteristic RPE morphology and pigmentation on 
an ultrathin parylene-C substrate (Fig. 4a-c).  These hESC-derived RPE cells express the 
tight junction marker ZO-1, which demonstrates the formation of an epithelial layer (Fig. 
4d).  Typical apical microvilli develop, which are essential to the phagocytic function of 
RPE in maintaining photoreceptor outer segments in vivo (Fig. 4e-f). This proof of concept 
culture demonstrates that hESC-derived RPE can attain confluency and form a polarized 
monolayer on parylene-C.  
Two recent studies demonstrated that hESC-derived RPE seeded on an ultrathin 
parylene-C substrate 1) do not elicit an immune response in immunocompromised nude rats 
[52] and 2) can be effectively transplanted into the subretinal space of a Royal College of 
Surgeons (RCS) rat, an animal model for blindness [80].   
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Figure 4. hESC-derived RPE cells cultured on the ultrathin parylene-C substrate.  Images 
taken (a) one day (b) one week and (c) four weeks after seeding hESC-derived RPE onto the 
ultrathin parylene-C substrate demonstrate the cells’ ability to attach, proliferate and form a 
confluent, pigmented monolayer. (d) Immunostaining for the tight junction marker, ZO-1, 
reveals the typical cobblestone morphology and the epithelial trait of the RPE. (e) Top-view 
and (f) cross-section scanning electron micrographs confirm an established, polarized 
monolayer on the parylene-C substrate with the RPE microvilli oriented on the apical side. 
© Biomedical Microdevices (2012) 14(4) pp 659-667, "Mesh-supported submicron 
parylene-C membranes for culturing retinal pigment epithelial cells" Lu B, Zhu D, Hinton 
D, Humayun M, Tai YC, Fig 9.  – with kind permission from Springer Science+Business 
Media. 
 
In order to compare the immunogenicity of an hESC-derived RPE cell suspension to 
a cellular monolayer on an ultrathin parylene-C substrate, each condition was applied to the 
subretinal space of an athymic nude rat, which is an immunocompromised rat lacking T-
cells [52, 82]. Neither resulted in tumor formation, but the supportive parylene substrate 
significantly improved the viability of the hESC-derived RPE 12 months post implantation 
when compared to the injected suspension.  Specifically, 50% of the 2700 cells that were 
transplanted on the substrate were detected by human RPE markers one year post-surgery, 
while only 25% of the 100,000 cells that were injected as a cell suspension could be found 
in the eye [52].  Additionally, the transplantable substrate significantly promoted the 
maintenance of a polarized monolayer while the suspension cells formed clumps in the 
subretinal space.  It has previously been demonstrated that once in suspension, RPE 
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reattachment rate is directly proportional to cell survival [83].  This demonstrates obvious 
benefits to using a substrate.  Cells attached to a scaffold have an increased likelihood to 
survive, form a polarized monolayer, and to be precisely delivered to a specific destination.  
Demonstrating efficacious delivery of a stem cell-based product on a substrate and 
functional recovery in an animal model is an essential prerequisite before proceeding to 
clinical trials.  Researchers have demonstrated the feasibility of transplanting hESC-derived 
RPE on parylene-C into the subretinal space of the RCS rat, an animal model of blindness 
[80].  In 1953, Professor Sorsby at the Royal College of Surgeons in London inbred rats 
prone to heritable cataracts for over nine generations.  Later in 1960, Sidman and Pearlstein 
inbred these animals for 5-9 additional generations and entitled the resulting strain the Royal 
College of Surgeons (RCS) rat [84].  These animals are homozygous recessive for an allele 
of the pink-eyed dilution gene, p, which affected the RPE pigmentation in vivo but not in 
vitro, and to a much lesser extent, the body size [84].  This strain became notorious for its 
retinal degeneration which starts 18 days after birth due to accumulation of rod outer 
segments. [85].   The RPE in the RCS rat cannot perform phagocytosis to remove the excess 
outer segments due to a mutation in the receptor tyrosine kinase gene Mertk [86].  Therefore, 
these animals start to become blind by 18 days after birth due to an excess accumulation of 
photoreceptor outer segments and experience a total loss of vision within 3 months [86, 87].  
Vision in RCS rats may be rescued by subretinal cell-suspension injections of fetal rat RPE 
[88], adult human ARPE19, genetically modified h1RPE7 [89] hESC-RPE [16] and iPSC-
RPE [90].   However, the RCS rat does not emulate the disease phenotype of drusen deposits 
nor neovascularization as seen in AMD, but this strain does offer an animal model in which 
to test the viability, functionality, and potential immunogenicity of transplanted RPE cells 
on a substrate.  The RCS rat model system has also been used to study retinitis pigmentosa. 
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Ultrathin parylene-C membranes carrying therapeutic hESC-derived RPE have also 
been successfully introduced into the subretinal space of the RCS rat and normal 
Copenhagen rats [80].   Proper placement of the transplant was confirmed by spectral-
domain optical coherence tomography (SD-OCT).  Although the procedure caused an 
expected retinal detachment, the tissue reattached within in one week.  Comparing the 
numbers of hESC-derived RPE adhered to the substrate pre- and post-transplantation 
revealed less than 2% of the cells were dislodged during surgery.  Specifically, the cell loss 
was observed primarily at the edges of the substrate, leaving the cells in the center of the 
patch seemingly undisturbed [80].  Optokinetic assays [90] that measure visual rescue by 
hESC-derived RPE on parylene-C substrates in vivo are currently being investigated. 
Cell Delivery Methods 
Transplanting an intact hESC-derived RPE monolayer can be technically challenging, 
which has stimulated the optimization of surgical approaches to ensure reproducibility of the 
procedure with protection and proper orientation of the graft. A fork-like implantation 
device has been used to implant synthetic scaffolds of parylene-C, silicon oxide and iridium 
oxide into the subretinal space of RCS rats [91].  Prior to implantation, the scaffold slides 
between two prongs of the tool, which confers mechanical stability, and once in the 
subretinal space, the prongs slide away while a central bar keeps the implant in place.  
However, implants used with this device were thicker than 10µm and had not been coated 
with cells.  This approach may be more appropriate for transplanting thicker electrical 
retinal prosthesis rather than ultrathin membranes coated with therapeutic cells [80, 91].  
These bulky implantation tools may obstruct the surgeon’s view, which could result in 
damage to the optic nerve and retina.  An alternate technique demonstrated protection of 
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human fetal RPE by encapsulating the cells grown on a rigid-elastic polyester substrate, 
polyethylene terephthalate (PET) with gelatin, which preserved the implant during an in 
vitro injection through a specially designed cannula [79].  However, in order to avoid batch-
to-batch variation of naturally derived products such as gelatin, synthetic platform devices 
are preferred over organic substrates when protecting the specialized monolayer grown on 
an ultrathin substrate. 
To transplant hESC-derived RPE grown on an ultrathin parylene-C membrane into the 
subretinal space of the RCS rat, the Humayun group has developed an implantation tool that 
supports and protects the delicate cargo and allows for specific orientation during delivery.  
The cell and substrate implant rests on a thicker (10µm) parylene plate and is secured in 
place during the surgery by raised barriers which are 30µm high.  Together, this 
implantation device and its cargo remains sufficiently sturdy to endure the shear force of the 
surgery, but is not too stiff to cause injury to the surrounding soft retinal tissue.  The 
implantation plate and its therapeutic cargo are delivered into the subretinal space with 
forceps.  Once in the desired location, forceps maintain the position of the implant while the 
tool is withdrawn.  In contrast to cumbersome transplantation devices that may interfere 
with the surgeon’s view and result in accidental damage, this thin parylene platform device 
is only slightly wider than the implant itself [80].  Additional tools must be designed when 
transplanting therapeutic cells on a substrate into larger mammals. 
D.  Future Directions 
Monitoring stem cell-derived RPE post-transplantation is essential to fully assess their 
integration into host tissue.  To this end, human-specific markers such as Tra-1-85 can be 
used to distinguish the hESC-derived cells from the host animal tissue [52].  Furthermore, 
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fluorescent reporters of genes of interest could be used in animal models.  Novel methods 
for labeling the transplanted human cells are needed to allow researchers to evaluate proper 
monolayer orientation and integration as well as to detect any unwanted migration or 
dedifferentiation. 
Transplantation of healthy hESC-derived RPE on parylene-C as discussed in this chapter 
may only treat early stages of AMD since photoreceptors would already have perished in the 
progressed form of the disease.  A plethora of protocols describe photoreceptor 
differentiation from hESCs [33, 40, 48], and hESC-derived retinal progenitors have been 
demonstrated to integrate with host neural tissue and restore some visual response in blind 
mice [92, 93].  However, photoreceptors cannot be restored in AMD patients unless the 
underlying RPE is also functional.   Therefore, in order to rescue photoreceptors and RPE in 
late-AMD patients, scaffolds supporting both cell types must be designed.    
In 2014, we stand at the threshold of using pluripotent stem cell based products as a 
powerful tool in regenerative medicine.  Human embryonic stem cells possess the ability to 
generate any cell type in the body, which offers an unlimited source of material for 
replacement therapeutics.  Synthetic substrates may ensure the support and directed delivery 
of the hESC-derived cells in a myriad of diseases.  If successful, pluripotent stem cell-
derived products in combination with substrates may cure currently untreatable diseases, 
replace expensive palliative medications, and restore quality of life to previously afflicted 
patients. 
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Abstract 
Age-related macular degeneration (AMD), a leading cause of blindness, is 
characterized by the death of the retinal pigmented epithelium (RPE), which is a monolayer 
posterior to the retina that supports the photoreceptors.  Human embryonic stem cells 
(hESCs) can generate an unlimited source of RPE for cellular therapies, and clinical trials 
have been initiated.  However, protocols for RPE derivation using defined conditions free of 
non-human derivatives (xeno-free) are preferred for clinical translation and to avoid 
exposing AMD patients to animal-derived products which could incite an immune response.  
In this study, we compared the maintenance of hESCs and their differentiation into RPE 
using Matrigel®, Synthemax®-R Surface and Synthemax®II-SC Substrate. The latter is a 
novel, synthetic, animal-derived component-free (ACF), RGD peptide-containing 
copolymer produced under good manufacturing practices (GMP) and is designed for stem 
cell culture.  This report demonstrates that Synthemax®II-SC supports long term culture of 
H9 and H14 hESC lines and permits efficient differentiation of hESCs into functional RPE.  
Expression of RPE-specific markers was assessed by flow cytometry, qPCR, and 
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immunocytochemistry, and RPE function was determined by phagocytosis of rod outer 
segments and secretion of pigment epithelium-derived factor (PEDF).  Both hESCs and 
hESC-derived RPE maintained normal karyotypes after long-term culture on 
Synthemax®II-SC.   Furthermore, RPE generated on Synthemax®II-SC are functional when 
seeded onto parylene-C scaffolds designed for clinical use.  These experiments suggest that 
Synthemax®II-SC is a suitable, defined substrate for hESC culture and the xeno-free 
derivation of RPE for cellular therapies.   
 
Introduction 
Age-related macular degeneration (AMD) is the leading cause of blindness in people 
over 65 years of age in industrialized countries, accounting for 8.7% of the world’s blind 
population, and it is projected that annual costs to the US federal government will exceed 
$845 million by 2021 1-3.  The early stages of this disease involve the dysfunction of the 
retinal pigmented epithelium (RPE).  The RPE maintains the health of the photoreceptors 
through phagocytosis of damaged outer segments, transporting and secreting ions and 
growth factors across the blood-retina barrier, isomerizing all-trans to 11-cis-retinal to 
perpetuate the visual cycle, absorbing stray light and limiting oxidation in the eye 4-6.  AMD 
manifests in two types.  Exudative or “wet” AMD is characterized by choroidal 
neovascularization into the retina, and can be mitigated by palliative intraocular injections of 
angiogenesis inhibitors like Avastin®, Lucentis® or EYLEA®.   However, 90% of AMD 
patients suffer from the “dry” form, which can lead to the geographic atrophy of the RPE 
and photoreceptors in the macular region of the retina 7.  As AMD progresses, the RPE 
degrade, causing the photoreceptors to deteriorate which leads to an incapacitating loss of 
vision8.   
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Currently, clinical studies are investigating the efficacy of transplanting non-
autologous RPE generated from human embryonic stem cells (hESC-RPE) and induced 
pluripotent stem cells (iPSC-RPE) as a means to restore vision in AMD patients 9-11.  These 
pluripotent stem cell-derived RPE have already demonstrated visual rescue in an animal 
model of retinal degeneration, the Royal College of Surgeons (RCS) rat12,13.  A preliminary 
study of one dry AMD patient injected with a suspension of hESC-RPE cells reported no 
tumor formation or adverse events after four months 9.  However, diseased retinas among 
patients will display varying degrees of degeneration, and since a suspension of RPE cells is 
extremely dissimilar to the endogenous organization, it is difficult to predict the efficacy of 
bolus injections as a therapy for the entire AMD population.  Alternatively, other groups are 
progressing to clinical trials using transplantable scaffolds, which provide a solid surface to 
promote a polarized RPE monolayer, enable site-specific delivery of the therapeutic cells, 
and confer support in a diseased environment 14,15.  To this end, ultrathin parylene-C 
scaffolds have been engineered to provide a transplantable, semi-permeable scaffold to 
support therapeutic hESC-RPE in the subretinal space 16,17.   
Methods to culture and differentiate pluripotent stem cells into RPE often use 
xenogeneic mouse embryonic fibroblasts (MEFs) or Matrigel®, a substrate derived from the 
Engelbreth-Holm-Swarm murine sarcoma 9,11-13,18.  These conditions present a possibility of 
exposing therapeutic cells to animal-derived immunogens, viruses and other undefined 
components such as growth factors, collagenases and plasminogen activators 19-21.  Recent 
efforts to derive hESC-RPE without using non-human animal products have co-cultured 
hESCs with human foreskin fibroblasts and substrates comprised of full-length human 
proteins 22-24.  However, due to the natural variability among fibroblast cell lines or batches 
of purified proteins, synthetic substrates may be more desirable for consistent generation of 
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clinical-grade therapies.  Synthemax®-R is a synthetic, animal-derived component-free 
(ACF) substrate designed for cell culture and is composed of a biologically active peptide 
derived from the human extracellular matrix (ECM) protein vitronectin that is covalently 
conjugated to the tissue culture vessel by an acrylate moiety25.   ACF conditions do not 
employ any animal-derived products, including human, and this distinguishes it from xeno-
free conditions.  Synthemax®-R has been shown to support hESC and iPSC growth 25-31 and 
their differentiation into ocular cell types 26,31,32.  However, Synthemax®-R is only available 
in limited styles of tissue culture plates, thus restricting its range of applications and its 
ability to scale-up the manufacture of therapeutic cells. Synthemax®-II SC Substrate, is a 
novel ACF, good manufacturing practices (GMP)-compliant peptide-copolymer that self-
adsorbs onto tissue culture plastic or glass surfaces.  This feature imparts versatility when 
scaling-up production of therapeutic cells and facilitates a wider array of characterization 
assays.  The Synthemax®II-SC peptide includes the RGD containing sequence from the 
ECM protein vitronectin, KGGPQVTRGDVFTMP, which promotes adhesion in a variety 
of cells 25,33,34.  To date, Synthemax®II-SC has been shown to support human iPSCs and 
human mesenchymal stem cells35,36.  Here we validate Synthemax®II-SC as a viable 
substrate for the defined culture of hESCs and hESC-RPE.  We have found that pluripotent 
H9 and H14 hESC lines can be maintained on Synthemax®II-SC and retain a normal 
karyotype for more than 16 passages.  These lines differentiate into hESC-RPE with a 
significantly higher yield than hESCs maintained on Synthemax®-R Surface.  Also, hESC-
RPE cultured on Synthemax®II-SC are similar to hESC-RPE derived on Matrigel® and 
Synthemax®-R with respect to gene expression and function.   Furthermore, hESC-RPE 
derived on Synthemax®II-SC retain RPE identity and function when seeded onto 
transplantable parylene-C scaffolds.  
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Materials and Methods 
hESC Culture  
Cultures of hESC lines H9 and H14 (WiCell Research Institute) were maintained on 
Matrigel® hESC-qualified matrix (Corning® #354277) in mTeSR™1 (STEMCELL 
Technologies, #05850).   Stem cell colonies were manually passaged every 4-7 days: 
differentiated regions were removed followed by manual dissection of pluripotent colonies. 
To compare hESCs grown on Synthemax®II-SC Substrate to other commercially available 
substrates, hESCs were passaged onto tissue culture treated plates coated with 
Corning®Matrigel®, Corning® Synthemax®-R Surface (#3979, 3984, 3977XX1), and 
Synthemax®II-SC Substrate (Cat#3536-XX1, Lot#DEV45-10) and were serially passaged 
by manual dissection.  Similar number and size of colonies were chosen for propagation on 
the 3 surfaces.   hESCs between passages 40-49 were used for characterization.  For 
differentiation into germ layers, hESCs on Synthemax®II-SC were differentiated for 10 
days in DMEM/F12+GlutaMAX™I, 20% KnockOut Serum Replacement, 1x non-essential 
amino acids, and 0.1mM β-mercaptoethanol (all reagents from Life Technologies). 
 
Differentiation, Enrichment and Culture of RPE  
Pluripotent hESCs were spontaneously differentiated on the substrates of interest for 115 
days in XVIVO™10 medium (Lonza #04-743Q) with Normocin (Invivogen #ant-nr-1).  
Pigmented cells were enriched by treatment with TrypLE Select (Gibco #12563-011), 
followed by manual removal of non-pigmented cells.  Remaining RPE were dissociated with 
TrypLE Select for 5 min. at 37°C, passed through a 40µm nylon cell strainer and seeded on 
the substrates of interest at 1.5x105 cells/cm2.   RPE cultures were maintained in 
XVIVO™10 medium and passaged with TrypLE Select every 28 days for 3 months and 
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seeded at 1.0x105 cells/cm2 onto Matrigel®, Synthemax®-R, and Synthemax®II-SC 
Substrate (Cat#3536-XX1, Lot#28512016, 14413006, 22413018).  Cells at passage 2 day 28 
were used for characterization.  The “Matrigel”, “Synthemax-R” and “Synthemax-II” 
designations describe the condition of hESCs propagated, differentiated, enriched and 
passaged as RPE solely on the Matrigel®, Synthemax®-R, and Synthemax®II-SC 
substrates, respectively.  “Mg-SR” denotes the condition of undifferentiated hESCs grown 
and differentiated on Matrigel®, then enriched and grown as RPE on Synthemax®-R as 
described previously 17,37.   
 
Fetal Human RPE (fRPE) Culture 
Fetal human RPE were a kind gift of Dean Bok (University of California Los Angeles) 
and Lincoln Johnson (Center for the Study of Macular Degeneration, UC Santa Barbara).  
fRPE were maintained in Miller medium38: α-Modification MEM media (Sigma M4526) 
supplemented with non-essential amino acids (Gibco #11140-050), GlutaMax-I (Life 
Technologies 35050), N1 supplement (Sigma N6530), 1mL of THT per 500mL of media 
(0.0065µg/mL triiodothyronine, Sigma T5516; 10µgmL hydrocortisone, Sigma H0396; 
125mg/mL taurine, Sigma T0625) and heat-inactivated fetal bovine serum (15% for seeding 
fRPE, 5% for fRPE maintenance) (Atlas Biologicals F-0500A).   
 
Synthemax®II-SC Substrate Vessel Coating 
Tissue culture vessels were coated with Synthemax®II-SC according to the 
manufacturer’s recommendations.  Briefly, Synthemax®II-SC powder was resuspended to 
1mg/mL in HyClone HyPure Cell Culture Grade Water (AWK21536) and stored at 4°C for 
1 month or further diluted 1:40 (0.025mg/mL) to coat tissue culture vessels (Corning 
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CellBIND® Surface, #3335; Costar® cell culture plates and flasks, #3516, 3603, 430641, 
431082), Millicell-HA inserts (Millipore, PIHA01250), and Thermo Lab-Tek Permanox 
Chamber Slides (#177445) at 5µg/cm2 for 2 hours at room temperature.  Remaining 
Synthemax®II-SC solution was then aspirated and the air-dried vessels were used 
immediately or stored at 4°C for up to 3 months.  
 
Immunocytochemistry 
Cells were rinsed with warm DPBS (Gibco #14190-144) and fixed with 4.0% 
paraformaldehyde (Electron Microscopy Sciences #15710) in 0.1M sodium cacodylate 
buffer (Electron Microscopy Sciences #11652) for 5 minutes at 4°C.  Fixed cells were 
blocked with 1% BSA (Gibco #15260), 1% goat serum (Sigma #G9023) and 0.1% Triton-X 
(Roche 11332481001) in PBS for 1 hour at 4°C.  Primary antibodies diluted in block 
solution were applied overnight at 4°C (msαOct4, 1:100 Santa Cruz sc-5279; msαTra1-81, 
1:100 Millipore MAB4381; rbαSall4, 1:800 Abcam ab29112; msαTra1-60, 1:100 Millipore 
MAB4360, msαHMB45 (PMEL17), 1:100 Dako M0634; msαBestrophin, 1:100 Abcam 
ab2182; msαZO-1, 1:100 Life Technologies 339100; rbαOtx2, 1:4000 Millipore 9566).  
Cells were rinsed 3 times with PBS and secondary antibodies were diluted 1:300 in block 
solution and applied for 30 minutes at 4°C (Alexa Fluor® 546 gtα rb A11035; Alexa Fluor® 
488 gt-αms IgG, IgM A10680; and Alexa Fluor® 488 gt-αms IgM A21042; Life 
Technologies).  Cells were incubated with Hoechst nuclear stain (8µg/mL, Sigma 33258) for 
5 minutes at room temperature in the dark and rinsed 3x with PBS.  Slides were mounted 
with Pro-Long® Gold Antifade Reagent (Life Technologies #P36930) and imaged with 
QCapture Pro software on Olympus IX71 or BX51 fluorescence microscopes.    
Quantitative Polymerase Chain Reaction 
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 For RNA collection, whole wells of hESCs ready for passage were harvested from 
each substrate; differentiated regions were not removed prior to harvest.  RNA was 
harvested using the RNeasy Plus kit (QIAGEN #74136) and converted to cDNA (iScript 
cDNA Synthesis kit, Bio-Rad #170-8891).  For hESC-RPE, 1.5x105 cells were collected at 
passage 2 day 28 and processed with the Cells-to-Ct kit (Ambion #4399002).  Real-time 
qPCR was completed with TaqMan Gene Expression Assays (Life Technologies #4351372, 
Supplemental Table 1) in TaqMan Gene Expression Master Mix (Life Technologies # 
4369016) using a Bio-Rad CFX96™Real-Time System.   Data was analyzed with the Bio-
Rad CFX Manager software. 
 
Flow Cytometry 
Whole wells of hESCs ready for passage were harvested from each substrate; 
differentiated regions were not removed prior to harvest.  hESCs were dissociated by 5-13 
minute incubations in TrypLE Select at 37°C and diluted 1:5 in fresh medium.  For hESC-
RPE, 1x106 cells were collected at passage 2 day 28.  For fixation, cells were centrifuged at 
1500rpm for 3 minutes, washed in 0.5% BSA Fraction V (Gibco #15260-037) in PBS, and 
fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature in the dark.  Cells 
were pelleted at 2300rpm for 3 minutes and permeabilized with 0.2% Triton-X (Roche 
11332481001), 0.1% BSA Fraction V in PBS for 3 minutes at room temperature.  Fixed 
cells were stored at 4°C in 0.5% BSA until stained.   
Cells were stained with primary antibodies diluted in 3% BSA and PBS for 30 
minutes at 4°C (hESCs) or room temperature (RPE) (PE-Oct4 IgG, 1:5 BD Pharm 560186; 
PE-Isotype IgG Control, 1:5 BD Pharm 559320; PE-SSEA4 IgG3, 0.1µg/ml R&D Systems 
FAB1435P; Mouse IgG3-RPE Clone B10, 0.1µg/ml Southern Biotech; HMB45 (PMEL17), 
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0.1µg/ml Dako M0634; Mouse IgG1 isotype control, Dako X0931).   Samples were stained 
with a secondary antibody for 30 minutes at room temperature (AlexaFluor® 488, Life 
Technologies A21202).  Cells were rinsed with 0.5% BSA and data was collected on a BD 
Accuri®C6 Flow Cytometer with 10,000 gated events per sample.  Gates were set to exclude 
99.0% of the population stained with the isotype control of the primary antibody.  Data was 
analyzed with FCS Express (De Novo Software). 
 
Karyotype 
Cells were seeded in a T-25 flask (Corning #430168) that was coated with Matrigel® or 
Synthemax®II-SC Substrate and shipped in log-phase overnight to Cell Line Genetics Inc. 
for G-band karyotyping. 
 
Pigment Quantification 
ImageJ (http://imagej.nih.gov/ij/) was used to quantify pigmented area in the 
differentiated hESC cultures. Briefly, photographs of the differentiated hESC-RPE plates 
were converted to 8-bit images.  Scale was set to 500 pixels:17.3 mm for a 6-well plate.  The 
well area was selected, contrast enhanced (20%, Normalize, Equalize histogram), 
background subtracted (15%, Light Background, disabled smoothing), converted to binary, 
and analyzed for particle size (size: 0.02-10mm2).   
 
PEDF ELISA 
To compare secretion of pigment epithelium-derived factor (PEDF), hESC-RPE derived 
on different substrates were seeded onto transwell Millicell-HA inserts (Millipore, 
PIHA01250) coated with 2.63 µg/cm2 human vitronectin (BD BioSciences 354238) or 
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Synthemax®II-SC.   Cells were maintained in 400µL XVIVO™10 within the insert and 
600µL in the well.  Apical and basal supernatants were collected on passage 2 day 30, 72 
hours post-medium change, snap-frozen in liquid nitrogen and stored at -80°C.  Supernatants 
from hESC-RPE on parylene-C membranes were collected 30 days after thaw/seed, 24 hours 
post medium change.  Supernatants were diluted 1:5000; concentration of PEDF was 
determined with the PEDF ELISA kit (Bioproducts MD #PED613-Human) according to the 
manufacturer’s instructions.  Optical density was measured at 450 nm.   
 
Rod Outer Segment (ROS) Phagocytosis  
The ROS phagocytosis assay was performed as previously described 39.   Briefly, hESC-
RPE, human fRPE and ARPE19 cells were seeded in quadruplicate onto gelatin, 
Synthemax®II-SC or human vitronectin-coated 96 well plates at 1x105 cells/cm2 and 
maintained in Miller medium.   Rod outer segments were isolated from fresh bovine retinas, 
labeled with fluorescein isothiocyanate (FluoReporter FITC Protein Labeling kit, Life 
Technologies #F6434) and resuspended in 2.5% sucrose in Miller medium.  Four weeks 
after plating, confluent cells were incubated with 1x106 labeled ROS, with or without 
62.5µg/ml of the anti-αvβ5 function blocking antibody (Abcam #ab24694) or the isotype 
control (Abcam #ab18447) for 5 hours at 37°C in 5% CO2.   Unbound ROS were removed 
with six rinses of warm 2.5% sucrose in PBS and extracellular fluorescence was quenched 
with 0.4% trypan blue (Corning #25-900Cl) for 20 minutes at 37°C.  Trypan blue was 
replaced with 40µL of PBS-sucrose and internalized fluorescence was imaged with an 
Olympus IX71.  ImageJ software was used to calculate the internalized fluorescence 
intensity by pixel densitometry.   Fluorescent signals from each condition were normalized 
to the ARPE19 signal. 
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hESC-RPE on Parylene-C 
Mesh-supported submicron parylene-C membranes were manufactured as described 
previously 16.  These scaffolds were coated with human vitronectin in a 48 well plate; hESC-
RPE derived on Synthemax®II-SC or by the Mg-SR method were thawed and seeded on the 
membrane at 1.5x105 cells/well and grown for 30 days in XVIVO™10 medium without 
antibiotics. 
 
A. Novel Substrate Supports Human Embryonic Stem Cells 
Results  
Synthemax®II-SC Supports Long Term Culture of H9 and H14 hESCs 
Matrigel® is one of the most widely used cell-free substrates for hESC culture 18,40.  
Therefore, morphology and gene expression of hESCs cultured on Synthemax®II-SC were 
compared to hESCs on Matrigel®.   Comparisons were also made to hESCs maintained on 
Synthemax®-R to determine if Synthemax®II-SC is an acceptable alternative ACF 
substrate.   
Overall, hESC colonies cultured on Synthemax®II-SC exhibited morphology similar 
to hESCs grown on Matrigel®, characterized by a homogenous layer of small, tightly 
packed cells and a distinct colony border.  Colonies on Synthemax®II-SC generally 
appeared larger than those grown on Synthemax®-R but were more compact than those 
grown on Matrigel® (Fig. 5A; supplemental Fig. 1).  To investigate the percent of cells 
expressing pluripotency markers Oct4 and SSEA4, flow cytometry was carried out on 
cultures at passages 1, 3, 5, and 9 (Fig. 5B; supplemental Fig. 2A).  While hESC cultures on 
Matrigel® showed consistent expression of both pluripotency markers, a decrease in 
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expression of Oct4 was observed on both xeno-free surfaces at some passages.  Additional 
markers of undifferentiated cells were examined by qPCR and immunocytochemistry.  By 
passage 7, hESCs on Synthemax®II-SC and Matrigel® expressed similar levels of 
pluripotency-associated mRNAs  (Fig.5 C; supplemental Fig. 2B) and had similar colony 
morphologies.  Throughout all passages, hESCs on Synthemax®II-SC and Matrigel® 
expressed the pluripotent surface antigens SSEA4, Tra1-60 and Tra1-81 along with nuclear 
hESC transcription factors Oct4 and Sall4 (Fig. 5 B,F; supplemental Fig. 2 A,B).  
To determine if long-term cultures of H9 and H14 hESCs on Synthemax®II-SC 
maintain a normal karyotype, these lines were subcultured for 23 and 16 passages, 
respectively.  Each line maintained a normal human karyotype (Fig. 5D; supplemental Fig. 
2D).  The differentiation potential of hESCs grown on Synthemax®II-SC was investigated 
by culturing cells in a differentiation medium for 10 days.  These differentiated cells 
expressed markers from the 3 germ layers at higher levels than the undifferentiated cultures.  
Markers of ectoderm (Microtubule associated protein 2, MAP2)35, mesoderm (T-Box 
Protein 6, Tbx6) 36, and endoderm (α-feto protein, AFP)41,42 were detected (Fig. 5E; 
supplemental Fig. 2C).  
Taken together, these data demonstrate that Synthemax®II-SC is a suitable, ACF 
substrate for the maintenance of hESCs that express canonical pluripotency markers and can 
differentiate into all three germ layers. 
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Figure 5.  Characterization of hESCs cultured on Synthemax®II-SC, Synthemax®-R and 
Matrigel®.  (A) Representative phase contrast micrographs of H9 and H14 hESC colony 
morphology after 9 passages on the indicated substrate.  Scale bars = 200µm. (B) 
Representative flow cytometry histograms for pluripotency markers Oct4 and SSEA4 in H9 
cultures grown on the indicated substrate at passages 1, 3, 5 and 9. (C) Relative mRNA 
expression of pluripotency genes in H9 cultures grown on Synthemax®II-SC, Synthemax®-
R and Matrigel® at passages 1, 3, 5 and 9 as detected by qPCR.   (D) Normal karyotype of 
H9 hESCs maintained on Synthemax®II-SC for 23 passages.  (E) Relative mRNA 
expression of germ layer markers for H9 hESCs grown and differentiated on Synthemax®II-
SC as detected by qPCR.  (F)  H9 hESCs on Synthemax®II-SC stained for nuclear 
pluripotency transcription factors Oct4 and Sall4, and surface markers Tra1-81 and Tra1-60.  
Scale bar = 80µm. 
 
 
B. Xeno-Free Spontaneous hESC Differentiation into Functional RPE 
Synthemax®II-SC permits RPE differentiation from hESCs 
Since Synthemax®II-SC was found to support the defined culture of hESCs, we next 
investigated whether this substrate also permitted efficient, xeno-free differentiation of 
hESCs into RPE.  H9 and H14 hESC lines adapted to Matrigel®, Synthemax®-R, and 
Synthemax®II-SC were spontaneously differentiated into RPE by changing the growth 
medium to XVIVO™10, a xeno-free formulation lacking bFGF (Fig. 6).   During this 
process, pigmented foci appeared after 4 weeks and continued to enlarge over the next few 
months.  At 115 days post-differentiation, the area of pigmentation on each substrate was 
quantified (Fig. 6).   Unexpectedly, Synthemax®II-SC yielded significantly more pigmented 
area than Synthemax®-R (p < 0.01).  However, there was no difference in the amount of 
pigmented area produced on Matrigel® and Synthemax®II-SC.  This suggests that 
Synthemax®II-SC is an acceptable replacement for Matrigel® in the xeno-free production 
of clinical-grade RPE from hESCs. 
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Figure 6.  Spontaneous differentiation of hESC-RPE on Matrigel® and Synthemax®II-SC 
yield significantly more pigmented area than hESC-RPE on Synthemax®-R.  Top: 
Pigmented area in individual wells was calculated with ImageJ software after 115 days of 
differentiation.  Error bars denote standard deviation; ** p < 0.01, ttest.  Below: Three 
representative wells from a 6 well plate of differentiated hESC-RPE seeded on each 
substrate are shown.  Scale bar = 1cm. 
 
RPE cultured on Synthemax®II-SC maintain RPE identity 
Pigmented regions produced by spontaneous differentiation (Fig. 6) were manually 
isolated from non-pigmented cells in a process termed “enrichment.”  Protocols have been 
developed whereby hESCs are differentiated to RPE on Matrigel® and then enriched onto 
Synthemax®-R (Mg-SR method)16,17,44.  To investigate if Synthemax®II-SC can entirely 
replace Matrigel® for the growth of hESCs and their differentiation into RPE, we compared 
cultures maintained solely on Synthemax®II-SC to those produced using the Mg-SR 
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method.  Synthemax®II-SC hESC-RPE were also compared to cells produced solely on 
Synthemax®-R or Matrigel®. 
After 30 days in culture, the hESC-RPE produced on Synthemax®II-SC and 
Synthemax®-R qualitatively appeared darker than those produced on Matrigel® or by the 
Mg-SR method (Fig. 7A; supplemental Fig. 3A).  Interestingly, H9 hESC-RPE derived on 
Synthemax®II-SC expressed pigmentation markers to a similar extent as Mg-SR but 
expressed significantly more tyrosinase (Tyr) mRNA than RPE on Synthemax®-R at 
passage 2 day 28 (Fig. 7C).  H14-derived RPE did not exhibit this difference.  No significant 
difference was found in the expression of other pigmentation-related proteins PMEL17 and 
tyrosinase related protein-1 (Tyrp1) in either line of hESC-RPE.  All lines displayed the 
typical cobblestone morphology of cultured RPE.  A few lacunae, were observed in a 
minority of hESC-RPE cultures on Synthemax®II-SC, which may be related to the 
efficiency of enrichment and non-RPE paracrine signaling effects on tight junctions in the 
monolayer45 or uneven coating of the substrate (supplemental Fig. 4).  
The purity of the RPE population and efficiency of enrichment were measured at 
passage 2 day 28 by assessing the percentage of cells that express PMEL17, an essential 
structural protein for melanogenesis 46,47.  All cultures were over 95% positive for the 
protein PMEL17 and localization was confirmed by immunocytochemistry (Fig. 7B,E; 
supplemental Fig. 3B,C).  There was no significant difference in the expression of RPE65 
and RLBP1 transcripts, which are involved in the visual cycle6,48 nor the RPE  chloride 
channel, bestrophin-1 (BEST1) (Fig. 7C; supplemental Fig. 5A).  Furthermore, RPE 
produced on Synthemax®II-SC expressed RPE marker proteins with proper localization. 
The RPE master transcription factor Otx249,50 was visualized in the nucleus and  Zonula  
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Figure 7. Characterization of hESC-RPE derived on Synthemax®II-SC.  (A) Phase contrast 
and bright field images show the typical pigmentation and cobblestone morphology of H9 
hESC-RPE cultured on different surfaces are shown.  Mg-SR denotes the condition of 
culturing and differentiating hESCs on Matrigel® then enriching and propagating the hESC-
RPE on Synthemax®-R. Scale bar = 200µm.  (B) Representative flow cytometry histograms 
are shown for the premelanosome pigmentation marker PMEL17 and the pluripotency 
marker Oct4 (not detected) in H9-RPE at pass 2, day 28 on the indicated substrate.  (C) 
Expression of RPE marker genes in H9 hESC-RPE on the indicated substrates.  Fetal RPE 
(fRPE) served as a positive control.  n=3, * p < 0.05,ttest.  (D) Normal karyotype of H9 
hESC-RPE after spontaneous differentiation, enrichment and 3 passages on Synthemax®II-
SC.  (E)  Epifluorescent images are shown of H9 hESC-RPE derived on Synthemax®II-SC 
stained for the tight junction marker, ZO-1, RPE markers Otx2 and PMEL17, and the 
pluripotency marker Sall4 (not detected).  Nuclei were detected using Hoechst (blue, merged 
right panels). Scale bar = 50µm. 
 
 
Occludens-1 (ZO-1)6 immunoreactivity was observed at cell junctions, consistent with 
localization to tight junctions (Fig. 7E).   
One of the primary concerns regarding stem cell-derived therapies involves the 
potential of introducing tumorogenic, undifferentiated stem cells into patients51.  Therefore,  
expression of the pluripotency markers Oct4, Rex1 and Sall4 were assessed for all lines of 
H9 and H14 hESC-RPE.  All lines tested negative for these embryonic stem cell markers 
(Fig 7B; supplemental Figs. 3B,C; 5B,C).  Also, the proliferative marker mKi67 could not 
be detected in any of the hESC-RPE derived under different conditions, which suggested 
that the cells are quiescent and have exited the cell cycle (supplemental Fig. 5B,C).  
Furthermore, H9 and H14 hESCs that were grown, differentiated, enriched and maintained 
as RPE for 3 passages on Synthemax®II-SC retain a normal human karyotype (Fig. 7D; 
supplemental Fig. 3D).  These data demonstrate that hESC-RPE maintained in xeno-free 
conditions on Synthemax®II-SC retain an identity similar to RPE derived using the Mg-SR 
method.   
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RPE Derived on Synthemax®II-SC are Functional 
One of the primary functions of RPE in the retina is to internalize the shed photoreceptor 
outer segments by phagocytosis6,52,53.  The phagocytic function of hESC-RPE derived on 
Synthemax®II-SC was compared to RPE generated on the other substrates.  hESC-RPE on 
Synthemax®II-SC internalized FITC-labeled rod outer segments (ROS) at levels similar to 
the other hESC-RPE (Fig. 8A; supplemental Fig. 3E).  In the first steps of ROS 
phagocytosis, integrin αvβ5 physically binds the ROS which activates focal adhesion kinase 
(FAK) to stimulate receptor tyrosine kinase Mer (MerTK) to initiate ROS engulfment 52.  To 
test if phagocytosis occurred via this pathway, function blocking antibodies to integrin αvβ5 
or an isotype control antibody were added with the ROS.  Inhibiting αvβ5 significantly 
reduced the amount of internalized ROS compared to the isotype control, indicating hESC-
RPE derived on Synthemax®II-SC perform phagocytosis similarly to hESC-RPE derived on 
Matrigel®, Synthemax®-R or Mg-SR (p < 0.01) (Fig. 8A; supplemental Fig. 3E).  Since 
vitronectin-coated scaffolds are being developed as cellular therapies for AMD16, phagocytic 
function of hESC-RPE derived on Synthemax®II-SC was analyzed on human vitronectin-
coated plastic.  hESC-RPE derived under defined, xeno-free culture conditions using 
Synthemax®II-SC were capable of ROS phagocytic function when seeded on vitronectin-
coated surfaces and Synthemax®II-SC (p < 0.01) (Fig. 8B; supplemental Fig. 3F). 
 In addition to phagocytosis, RPE are known to secrete growth factors that support 
the health of the neural retina and its structural integrity 6.  Among these, is the apically 
secreted pigment epithelium-derived factor (PEDF), which protects photoreceptors from 
ischemia and light damage 54,55.  hESC-RPE derived on Synthemax®II-SC secrete 
significantly more PEDF on their apical side compared to the basolateral surface when 
seeded on either xeno-free human vitronectin or Synthemax®II-SC (p < 0.01) (Fig. 8C).  
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Figure 8: Functional  
characterization of H9 hESC-
RPE derived on Synthemax®II-
SC.   
(A) Phagocytosis of rod outer 
segments (ROS) by H9 hESC-
RPE derived on Matrigel®, 
Synthemax®-R, Synthemax®II-
SC or Mg-SR (hESCs grown 
and differentiated on Matrigel® 
then enriched as hESC-RPE on 
Synthemax®-R).  A function-
blocking antibody against αvβ5 
integrin, which is necessary for 
phagocytosis by RPE, 
significantly decreased 
internalization of ROS in all 
hESC-RPE when compared to 
the IgG isotype control, ** p < 
0.01, ttest.  Fetal RPE (fRPE) 
served as a positive control.   
(B) Phagocytosis of ROS by H9 
hESC-RPE derived on 
Synthemax®II-SC after seeding 
on the defined substrates 
Synthemax®II-SC and human 
vitronectin.  Phagocytic activity 
was significantly decreased with 
the function-blocking αvβ5 
antibody when compared to the 
IgG isotype control, **p < 0.01, 
ttest.   
(C) Significant apical secretion 
of pigment epithelial-derived 
factor (PEDF) by H9 hESC-RPE 
after seeding on surfaces coated 
with Synthemax®II-SC or 
human vitronectin, ** p < 0.01, 
ttest.   
(SR, S2, Mg-SR = hESC-RPE 
derived on Synthemax®-R, 
Synthemax®II-SC or Mg-SR, 
respectively; HuVn, human 
vitronectin; S2, Synthemax®II-
SC). 
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 Taken together, these data demonstrate that hESC-RPE derived under xeno-free 
conditions on the synthetic Synthemax®II-SC surface perform phagocytosis and apically 
secrete PEDF when seeded on defined substrates. 
 
H9 hESC-RPE Derived on Synthemax®II-SC Maintain RPE Identity and Function on 
Parylene-C Scaffolds  
 
Vitronectin-coated mesh-supported submicron parylene-C membranes have been 
developed as transplantable scaffolds to deliver hESC-RPE produced by the Mg-SR method 
into AMD patients 16,17,44.  To determine if Synthemax®II-SC can be used as a xeno-free 
alternative to the Mg-SR method to produce hESC-RPE, cells from these two conditions 
were cultured for 30 days on vitronectin-coated parylene-C scaffolds.  No difference in 
initial attachment was observed, and hESC-RPE derived under both conditions grew to 
confluent monolayers with cobblestone morphology (Fig. 9A).  Once again, darker 
pigmentation was observed in the hESC-RPE cultures grown on Synthemax®II-SC (Fig. 
9A,B).   However, there was no significant difference in expression levels of genes 
associated with pigmentation as measured by qPCR (Fig. 9C).  The mRNA encoding the 
melanocyte-specific Mitf-4 isoform (Mitf-M) was not detected, while variant 2 (Mitf-H), 
which is expressed during RPE development along with isoforms 1 and 7 (Mitf-A, -D), was 
observed (Fig. 9C) 56.  hESC-RPE derived under these two conditions expressed similar 
levels of RPE marker genes, RPE65, Best1 and RLPBP1.  The Synthemax®II-SC hESC-
RPE secreted slightly less PEDF than hESC-RPE derived using the Mg-SR method (16 vs. 
19.6 ng/mm2) (Fig. 9D).  Taken together, these data show that Synthemax®II-SC is a viable 
alternative to Matrigel® for the xeno-free derivation and culture of hESC-RPE on parylene-
C scaffolds. 
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Figure 9: Characterization of H9 hESC-RPE derived on Synthemax®II-SC vs. Mg-SR 
seeded onto parylene-C scaffolds (A) Bright field and phase contrast images of H9 hESC-
RPE cells grown for 30 days on parylene-C scaffolds.  hESC-RPE were derived on 
Synthemax®II-SC or by the Mg-SR method (hESCs grown and differentiated on Matrigel® 
then enriched as hESC-RPE on Synthemax®-R).  Ultrathin regions of the membrane appear 
as an array of circles in the micrographs. Scale bar = 200µm.  (B) Bright field images of 
three representative parylene-C scaffolds seeded with hESC-RPE in a 24 well plate, n=8, 
Scale bar = 1cm. Note darker pigmentation in the RPE derived on Synthemax®II-SC.  (C)  
Expression of RPE and pigmentation markers after 30 days on parylene-C scaffolds as 
detected by qPCR. n=3  (D) Quantification of PEDF protein secreted by hESC-RPE derived 
on Synthemax®II-SC or by the Mg-SR method after 30 days on parylene-C scaffolds. n=6, 
error is SEM, * p < 0.05, ttest. 
 
Discussion 
The advent of employing pluripotent stem cell-derived therapies to treat human 
diseases necessitates Good Manufacturing Practices and preferably, defined culture 
conditions that do not employ xenogeneic products 19.  However, some of the current 
methods to produce hESC-RPE use Matrigel®, a mixture of ECM proteins harvested from 
the Engelbreth-Holm-Swarm mouse sarcoma 16,17,44.  Co-culturing therapeutic cells with 
xenogeneic derivatives may inadvertently introduce non-human viruses that could 
potentially inoculate the patient post-transplantation.   Synthemax®II-SC is a novel, ACF, 
GMP-compliant copolymer containing an RGD peptide.  To date, it has been shown to 
support the growth of pluripotent human iPSCs as well as the large scale production of 
human mesenchymal stem cells 35,36.  Here, we present the first characterization of hESC 
cultures and the xeno-free derivation of RPE using Synthemax®II-SC.  Furthermore, we 
have shown that hESC-RPE maintained on Synthemax®II-SC are similar to RPE derived by 
the Mg-SR method when seeded onto transplantable parylene-C scaffolds.  These data show 
that Matrigel® can be entirely eliminated from the production of hESC-RPE and replaced 
with Synthemax®II-SC. 
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Qualitatively, hESC colonies were easier to passage on Synthemax®II-SC than 
Synthemax®-R because colonies on the latter substrate remained small and developed 
compact, differentiated centers, rendering the efficient passaging of undifferentiated cells 
difficult (supplemental Fig. 1). The observed restriction in colony size may be due to the 
slightly higher density of peptide on the Synthemax®-R Surface (8-12 pmole/mm2) 
compared to the recommended coating density for Synthemax®II-SC (5-10 pmole/mm2)25 .  
Consistent with this observation, a previous study showed that human iPSC colonies on 
Synthemax®-R were more compact than the Matrigel® controls30.  However, it is not 
uncommon to observe varying sizes of hESC colonies on various feeder-free substrates as 
demonstrated by a comparison of Matrigel®, CELLstart™, and vitronectin conducted by 
Yoon et al. 40.   
Introducing hESCs to new culture conditions has been shown to illicit various 
fluctuations in morphology and an increase in differentiation while the cells adapt to the new 
environment 58,59.  Previous studies have reported that hESCs undergo an adaption period 
once transferred to various feeder free substrates 60,61.  H9 and H14 hESCs transitioning to 
Synthemax®II-SC at passages 2 and 4, respectively, manifested dense differentiated areas 
harboring small regions devoid of cells within several colonies (supplemental Fig. 1A,C).  
This extent of differentiation was not observed in other passages.  However, it is known that 
healthy hESC cultures will experience a slight degree of differentiation in every passage, 
and some differentiation is expected 62.  In this regard, hESCs on Matrigel® consistently 
demonstrated the least amount of differentiated morphology throughout 9 passages.  Since 
the original cultures for these experiments were adapted to Matrigel®, the minimal 
differentiation observed in these cells is expected compared to the hESCs transitioning to a 
new substrate.  hESCs on Synthemax®II-SC appeared slightly more differentiated than cells 
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on Matrigel® but were routinely less than Synthemax®-R (supplemental Fig. 1).  After 
seven passages, hESCs on Synthemax®II-SC appeared very similar to those on Matrigel®.  
Therefore, only hESCs that had been cultured for seven or more passages on a given 
substrate were used for spontaneous differentiation into RPE.  To demonstrate pluripotency, 
hESCs maintained on Synthemax®II-SC and allowed to differentiate expressed markers of 
the three germ layers at higher levels than the undifferentiated hESCs (Fig. 5E; 
supplemental Fig 2C).  Microtubule associated protein 2 (MAP2) is expressed in neural 
ectoderm, and T-Box Protein 6 (Tbx6) is necessary for mesoderm development63,64.  Post-
implantation embryos synthesize α-feto protein (AFP) in the visceral endoderm of the 
developing yolk sac and later in the fetal liver41,42.  
Flow cytometric analysis of hESCs at passages 1, 3, 5 and 9 revealed stable 
expression of the pluripotency-associated surface antigen SSEA465 on all 3 substrates and a 
small subpopulation of cells negative for Oct4 on the synthetic surfaces (Fig. 5B; 
supplemental Fig. 2A).  A previous study demonstrated that hESCs beginning to 
differentiate into an early neural lineage maintained high levels of SSEA4 expression while 
Oct4 was progressively down-regulated 66.  The differentiated morphology seen in the 
cultures on the Synthemax® surfaces could likely account for the small population of cells 
negative for Oct4 by flow cytometry (Fig. 5B).  Despite the slightly smaller population 
positive for Oct4, we conclude that Synthemax®II-SC is a suitable, defined substrate for the 
maintenance of hESCs. 
 It is interesting that hESC-RPE on both the Synthemax®II-SC and Synthemax®-R 
display darker pigmentation than the other conditions.  RPE pigmentation performs a myriad 
of essential roles for vision such as protecting against harmful short-wavelength light, 
participating as an antioxidant to reduce oxidative damage, and even contributing to proper 
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retinal structure during development 6,67.  The macula is also reported to contain a higher 
concentration of pigment granules than the peripheral retina 68.   However, the hESC-RPE 
derived on Synthemax®II-SC express significantly higher tyrosinase (Tyr) mRNA than 
those on Synthemax®-R (Fig 7A,C).  The discrepancy between the Synthemax® cultures 
could be due to differential rates of RPE maturation on the various substrates.  During 
embryonic development of the optic cup, activation of the tyrosinase promoter initiates RPE 
maturation and melanogenesis 49,67.   RPE then begin to produce melanosomes, which are 
specialized organelles for melanin synthesis.  Tyrosinase, a heavily post-translationally 
modified enzyme, catalyzes the rate limiting step of melanin synthesis in developing 
melanosomes 47,67,69.  Pigment production in the RPE occurs during embryonic development 
however, and no melanogenesis nor melanosome assembly is thought to occur after 
gestation 69.  RPE manifesting darker pigmentation may be more mature and could thus be 
starting to reduce the expression of melanogenesis genes while the proteins persist.  
Differential expression of gene transcripts and proteins for tyrosinase have been previously 
been reported 70.  RPE pigmentation can vary considerably in vivo, however, and does not 
necessarily reflect on other functional capacities12. 
hESC-RPE derived under xeno-free conditions with Synthemax®II-SC demonstrated 
polarized secretory function and the ability of ROS phagocytosis.  Regarding the secretory 
function of hESC-RPE, polarized secretion of PEDF also testifies to the maturity of the 
cells.  Also, detecting significantly more PEDF on the apical side of the monolayer testifies 
to the integrity of the tight junctions that separate the apical and basolateral environments.  
hESC-RPE derived on Synthemax®II-SC secreted slightly less PEDF when seeded on 
parylene-C scaffolds compared to hESC-RPE derived using the Mg-SR method (Fig. 9).  
However, H9 hESC-RPE on parylene-C have been observed to secrete a range of apical 
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PEDF concentrations between 11-20 ng/mm2 of protein (in preparation).  hESC-RPE 
derived under xeno-free conditions with Synthemax®II-SC functioned similiarly to those 
derived on Matrigel® and Synthemax®-R in their ability to phagocytoze ROS and this 
function was significantly reduced in the presence of the function blocking antibody to αvβ5 
integrin.  ROS phagocytosis by H14-derived RPE on all substrates was significantly less 
than that of H9-derived RPE, but was similar to the positive control, fRPE (supplemental 
figure 3).   
In summary, we have found that Matrigel® can be replaced by the GMP-compliant 
substrate Synthemax®II-SC for the culture of hESCs and the production of hESC-RPE.  
hESCs cultured on Synthemax®II-SC express pluripotency markers and are capable of 
differentiation into cells expressing markers from the three germ layers.  The yield of 
pigmented cells on Synthemax®II-SC after spontaneous differentiation of hESCs is 
significantly more than the yield on an alternative ACF substrate, Synthemax®-R.  hESC-
RPE derived on Synthemax®II-SC express RPE markers, internalize ROS by phagocytosis, 
and secrete apical PEDF similarly to hESC-RPE derived on Matrigel®.    Taken together, 
this work validates the use of a novel, ACF substrate for the xeno-free production of hESC-
RPE that can translate to stem cell-based therapies for AMD. 
 
Conclusions 
hESC-derived therapies are expected to be a powerful tool in regenerative medicine, 
which requires defined, xeno-free culture conditions as the field moves forward.  Here, we 
demonstrate that a novel synthetic substrate, Synthemax®II-SC, supports pluripotent hESC 
cultures and promotes their efficient differentiation into functional RPE.   
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III. Rapid and Efficient Derivation of RPE from hESCS 
 
A. Development of a Directed Differentiation Protocol 
 
Britney Pennington co-authored the following chapter entitled “Rapid and Efficient Directed 
Differentiation of Human Pluripotent Stem Cells Into Retinal Pigmented Epithelium” with 
Dr. David E. Buchholz.  Dr. Buchholz wrote the text and Britney Pennington contributed 
work to optimize the timeline of factor application, to investigate a potential mechanism of 
PARP-1 inhibition mediated by nicotinamide to expedite the derivation of hESC-RPE, and 
the data required for Fig. 10B, D; Fig. 11D; Fig. 12A, B, C; Fig. 14A. 
 
This manuscript has been published by Alphamed Press in Stem Cells Translational 
Medicine 2013, 2:384-393 doi: 10.5966/sctm.2012-0163. 
 
 
Rapid and Efficient Directed Differentiation of Human Pluripotent Stem 
Cells Into Retinal Pigmented Epithelium 
 
David E. Buchholz, Britney O. Pennington, Roxanne H. Croze, Cassidy R. Hinman, Peter J. 
Coffey and Dennis O. Clegg 
 
 
Abstract 
 Controlling the differentiation of human pluripotent stem cells is the goal of many 
laboratories, both to study normal human development and to generate cells for 
transplantation. One important cell type under investigation is the retinal pigmented 
epithelium (RPE).  Age-related macular degeneration (AMD), the leading cause of blindness 
in the Western world, is caused by dysfunction and death of the RPE. Currently, RPE 
derived from human embryonic stem cells are in clinical trials for the treatment of AMD. 
Although protocols to generate RPE from human pluripotent stem cells have become more 
efficient since the first report in 2004, they are still time-consuming and relatively 
inefficient. We have found that the addition of defined factors at specific times leads to 
conversion of approximately 80% of the cells to an RPE phenotype in only 14 days. This 
protocol should be useful for rapidly generating RPE for transplantation as well as for 
studying RPE development in vitro. 
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Introduction 
 Age-related macular degeneration (AMD) is the leading cause of blindness in the 
aging population of the Western world [1]. AMD presents in two forms, wet and dry, caused 
by dysfunction and death of the retinal pigmented epithelium (RPE) through mechanisms 
still being resolved [2]. The wet form, characterized by neovascularization, can be 
effectively treated with monthly injections of antiangiogenic drugs such as Lucentis® 
(Genentech, South San Francisco, CA, http:// www.gene.com). Although effective, there is 
substantial cost and inconvenience associated with monthly injections into the back of the 
eye [3].  The dry form of AMD is characterized by drusenoid aggregates under the basal side 
of the RPE at early stages, which progresses to geographic atrophy with marked loss of RPE 
and photoreceptors. Currently there is no effective treatment for the dry form of AMD, 
which accounts for 80%–90% of AMD cases. 
Because the etiology of AMD is still under investigation, one focus of therapy has been 
on replacing diseased RPE through transplantation [4]. The feasibility of this approach has 
been demonstrated by autologous replacement of RPE in the macula, the central portion of 
the retina responsible for high acuity vision, via macular translocation or relocation of 
peripheral RPE to the macula [5–7]. Although somewhat effective, these surgeries are long 
and complicated. The derivation of RPE from pluripotent cells and their efficacy in 
preclinical models of retinal degeneration have led to the design of simpler transplantation 
strategies that are much faster and cost-effective. Two methods of transplantation 
predominate: a subretinal bolus injection of single cells and subretinal insertion of a patch of 
RPE grown in its native monolayer form [8, 9]. Currently, clinical trials are under way using 
RPE derived from human embryonic stem cells (hESCs) using the bolus injection approach, 
with clinical trials using the patch soon to follow. 
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The translation of pluripotent stem cell-derived RPE has moved rapidly toward the 
clinic, and researchers in the lab have also been working to increase both the speed and 
efficiency of RPE derivation. Initial work on human pluripotent stem cell RPE began when 
it was observed that hESCs allowed to “spontaneously” differentiate would give rise to a 
low percentage of RPE, easily identifiable by pigmentation; this work was later recapitulated 
with induced pluripotent stem cells [10 –12]. This is the paradigm currently being used to 
generate RPE for the clinic. Although reliable, it is extremely inefficient and time-
consuming, with an efficiency of ~1% after 1–2 months in culture (although this varies be- 
tween lines). RPE are typically not harvested until after 2–3 months in culture, to give 
pigmented foci time to expand. A major breakthrough in the directed differentiation of 
pluripotent stem cells to RPE came in 2010 when the addition of nicotinamide and Activin-
A was shown to increase the efficiency of RPE generation to 33% after 6 weeks as 
determined by the number of pigmented cells [13]. The highest reported efficiency of RPE 
generation was obtained by exposing pluripotent cells to basic fibroblast growth factor 
(bFGF), Noggin, retinoic acid, and Shh. An efficiency of ~60% Mitf+ cells after 60 days of 
differentiation was reported [14]. 
Interestingly, a report in 2006 showed that neural retinal progenitors could be generated 
with ~80% efficiency after 21 days of differentiation through the application of a handful of 
factors (insulin-like growth factor 1 [IGF1], Noggin, Dkk1, and bFGF) [15]. Because RPE 
and the neural retina arise from a common progenitor pool [16], we sought to determine 
whether this protocol could be altered to direct pluripotent stem cells to RPE with a similar 
efficiency. Through the combined use of the retinal inducing factors (IGF1, Noggin, Dkk1, 
and bFGF) and other factors (nicotinamide, Activin A, SU5402, and vasoactive intestinal 
peptide [VIP]) added at appropriate times, we have found that pluripotent stem cells could 
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be directed to RPE with an efficiency of ~80% based on Pmel17 expression. Importantly, 
these cells could be isolated as early as 14 days following the onset of differentiation. This 
protocol should be useful for quickly generating quantities of RPE for transplantation as 
well as for the study of RPE development. 
 
Materials and Methods 
Pluripotent Stem Cell Culture 
The human embryonic stem cell line H9 (WiCell Research Institute, Madison, WI, 
http://www.wicell.org) was maintained in Dulbecco’s Modified Eagle’s Medium: Nutrient 
Mixture F-12 (DMEM/F12) containing 2mM GlutaMAX-I, 20% knockout serum 
replacement, 0.1mM Modified Eagle’s Medium Non-Essential Amino Acids (MEM 
NEAA), 0.1mM β-mercaptoethanol (Invitrogen, Carlsbad, CA, http://www.invitrogen.com) 
and 4 ng/ml bFGF (Peprotech, Rocky Hill, NJ, http://www.peprotech.com) on a mitomycin 
C (Sigma-Aldrich, St. Louis, MO, http://www.sig- maaldrich.com)-treated mouse 
embryonic fibroblast feeder layer. H9s for flow cytometry were grown on growth factor-re- 
duced Matrigel (BD Biosciences, San Diego, CA, http://www. bdbiosciences.com) in 
mTESR1 (StemCell Technologies, Vancou- ver, BC, Canada, http://www.stemcell.com) 
medium. The human embryonic stem cell line UCSF4 (NIH registry no. 0044, University of 
California, San Francisco) was maintained on growth factor-reduced Matrigel (BD 
Biosciences) in mTESR1 me- dium (StemCell Technologies). The induced pluripotent stem 
cell line iPS(IMR90)-4 (IMR904) (kind gift of J. Thomson, University of Wisconsin and 
University of California, Santa Barbara) was maintained in DMEM/F12 containing 2 mM 
GlutaMAX-I, 20% knock- out serum replacement, 0.1 mM MEM NEAA, 0.1 mM β -
mercaptoethanol (Invitrogen) and 100 ng/ml recombinant zebrafish bFGF (gift of J. 
Thomson) on a mitomycinC (Sigma-Aldrich)-treated mouse embryonic fibroblast feeders.  
  63 
Differentiation Into Retinal Pigmented Epithelium 
Pluripotent stem cells were passaged directly onto Matrigel (BD Biosciences) in 
DMEM/F12 with 1x B27, 1x N2, and 1x NEAA (Invitrogen). From days 0 to 2, 50 ng/ml 
Noggin, 10 ng/ml Dkk1, and 10 ng/ml IGF1 (R&D Systems Inc., Minneapolis, MN, http:// 
www.rndsystems.com) and in some experiments 10 mM nicotinamide or 5 mM 3-
aminobenzamide (Sigma-Aldrich) were added to the base medium. From days 2 to 4, 10 
ng/ml Noggin, 10 ng/ml Dkk1, 10 ng/ml IGF1, and 5 ng/ml bFGF and in some experiments 
10 mM nicotinamide or 5 mM 3-aminobenzamide were added to the base medium. From 
days 4 to 6, 10 ng/ml Dkk1 and 10 ng/ml IGF1 and in some experiments 100 ng/ml Activin 
A (R&D Systems) were added to the base medium. From days 6 to 14, 100 ng/ml Activin A, 
10 µM SU5402 (EMD Millipore, Darmstadt, Ger- many, http://www.emdmillipore.com), 
and 1 µM VIP (Sigma- Aldrich) were added to the base medium. Control experiments were 
also performed in base media alone (DMEM/F12, B27, N2, and NEAA). 
The cells were mechanically enriched by scraping away cells with non-RPE 
morphology. Subsequently, the remaining RPE were digested using TrypLE Express 
(Invitrogen) for ~5 minutes at 37°C. The cells were passed through a 30-µm single-cell 
strainer and seeded onto Matrigel-coated tissue culture plastic, Transwell membranes 
(Corning Enterprises, Corning, NY, http:// www.corning.com), or CC2-treated chambered 
slides. Enriched cells were cultured in DMEM-high glucose with 1% fetal bovine serum 
(FBS), GlutaMAX, and sodium pyruvate (Invitrogen) for 30 days [17]. 
Hs27 and cultured fetal human RPE (kind gift of D. Bok) were cultured on Matrigel-
coated Transwell membranes in DMEM- high glucose with 1% FBS, GlutaMAX, and 
sodium pyruvate (Invitrogen). MeWo cells were cultured in DMEM/F12 GlutaMAX1 
(Invitrogen) with 10% fetal bovine serum (HyClone, Logan, UT, http://www.hyclone.com). 
  64 
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany, 
http://www.qiagen.com). cDNA was synthesized from 1 µg of RNA using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA, http://www.bio-rad.com). Primer pairs were designed 
to create a 75–200-base pair product (Beacon Design 4.0; Premier Biosoft International, 
Palo Alto, CA, http:// www.premierbiosoft.com). Quantitative real-time polymerase chain 
reaction (PCR) was carried out on a Bio-Rad MyIQ Single Color Real-Time PCR Detection 
System using the SYBR Green method [18]. Triplicate 20-µl reactions were run in a 96-well 
plate with half of the cDNA synthesis reaction used per plate. Primer specificity was 
confirmed by melting temperature analysis, gel electrophoresis, and direct sequencing (Iowa 
State DNA Facility, Ames, IA). The data were normalized to the geometric mean of the 
“housekeeping” genes: glyceraldehyde phosphate dehydrogenase (GAPDH), 
hydroxymethylbilane synthase (HMBS), and glucose phosphate isomerase (GPI) [19].  
 
Immunocytochemistry 
The cells were grown on Matrigel-coated 12-well tissue culture plates (days 0 –14) or 
enriched onto Matrigel-coated chambered slides and cultured for 1 month. For fixation, the 
plates and slides were washed with phosphate-buffered saline (PBS), fixed with 4% 
paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, for 15 minutes at 4°C, and 
stored in PBS at 4°C until labeling. The slides were washed with PBS, blocked with PBS 
containing 5% BSA and 0.1% NP40 in PBS for 1 hour at 4°C, treated with ice-cold 90% 
methanol for 5 minutes, and incubated with primary anti- bodies overnight at 4°C. The 
slides were incubated with an appropriate Alexa Fluor (Invitrogen)-conjugated secondary 
antibody (1:300) for 30 minutes at 4°C, stained with Hoechst (2 µg/ml) (Invitrogen) for 5 
minutes at room temperature, washed with PBS, and then imaged at room temperature using 
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an Olympus IX71 fluorescence microscope or an Olympus Fluoview FV10i confocal 
microscope (Olympus, Cen- ter Valley, PA, http://www.olympusamerica.com).  
 
Flow Cytometry 
The samples were fixed in 4% paraformaldehyde in PBS (Electron Microscopy 
Sciences, Hatfield, PA, http://www.emsdiasum. com/microscopy) and permeabilized with 
0.2% Triton X-100 (Roche, Indianapolis, IN, http://www.roche.com). The samples were 
labeled with primary or isotype control antibodies for 30 minutes at 4°C. Primary and 
isotype control antibodies that were not conjugated to fluorophores were labeled with 
fluorophore-conjugated secondary antibodies for 30 minutes at 4°C. The labeled samples 
were run on an Accuri C6 flow cytometer with CFlow collection software (BD Biosciences). 
Data analysis was performed on FCS Express 4 Flow Research Edition (De Novo Software, 
Thornhill, ON, Canada, http://www.denovosoftware. com). The positive percentage was 
based on a background level set at 1% positive expression in samples labeled with isotype 
control antibodies. 
 
Rod Outer Segment Phagocytosis 
Rod outer segment (ROS) phagocytosis assays were performed as previously described 
[20]. Bovine eyes were obtained fresh from Sierra Medical Inc. (Whittier, CA, 
http://www.sierra-medical. com); ROSs were purified from retinal extracts and fluorescently 
labeled using the FluoReporter FITC Protein Labeling Kit (Invitro- gen). The cells were 
seeded in quadruplicate on gelatin-coated wells in a 96-well plate at a concentration of 
25,000 –50,000 cells per well and allowed to grow to confluence for 4 weeks. The cells were 
then challenged with 1   106 fluorescein isothiocyanate- labeled ROSs per well with or 
without 50  g/ml anti- v 5 (ab24694; Abcam, Cambridge, U.K., http://www.abcam.com) 
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or 50  g/ml IgG1 control (ab9404; Abcam) for 5 hours at 37°C in 5% CO2. The wells were 
then vigorously washed five times with warm PBS to remove unbound ROSs. To determine 
the level of ROS internalization, an equal volume of 0.4% trypan blue was added to the PBS 
for 10 minutes to quench extracellular fluores- cence. Trypan blue was aspirated, and 40  l 
of PBS was added to the well to prevent the cells from drying out. The internalized ROSs 
were then documented in fluorescence photomicrographs. Fluorescence intensity was 
quantified by pixel densitometry us- ing ImageJ software (National Institutes of Health, 
Bethesda, MD) for photomicrograph analysis. Photomicrographs from three wells for each 
condition were averaged within each assay. Separate experiments were normalized to the 
positive control ARPE-19 cell line, which was assayed in each experiment. 
 
Results 
Nicotinamide Speeds Up Early Eye Field Differentiation 
Because nicotinamide had previously been shown to increase differentiation of RPE 
from pluripotent stem cells [13], we tested whether nicotinamide would influence 
differentiation at early stages of eye field development. In this first segment of differen- 
tiation, cell clumps are mechanically dissected from pluripotent stem cell colonies and 
seeded on Matrigel in the presence of IGF1, Noggin, and DKK1. On day 2, bFGF is added. 
The addition of nicotinamide to IGF1, Noggin, Dkk1, and bFGF significantly decreased 
expression of the pluripotency genes Oct4 and Nanog on day 4 compared with controls (Fig. 
10A, 10B). Expression of early neural/early eye field markers Lhx2 and Rax increased in the 
presence of nicotinamide on day 4 compared with controls; however, the increase in Rax 
was not significant (Fig. 10B). Interestingly, Pax6(-5a) expression was similar between 
nicotinamide and control conditions (Fig. 10B). Cells in the presence of nicotinamide 
rapidly adopted a radial/rosette morphology compared with control cells, which still 
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contained a large percentage of cells with undifferentiated morphology (Fig. 10C). Control 
cells expanded more rapidly than cells in nicotinamide. 
Nicotinamide can have many effects on cultured cells, including inhibition of poly(ADP-
ribose) polymerase (PARP), which can protect cells from oxidative stress [13, 21]. To 
examine the mechanism of nicotinamide induced differentiation, we tested the ability of 3-
aminobenzamide, an inhibitor of PARP, to recapitulate the effects of nicotinamide. 3-
Aminobenzamide reduced levels of Oct4 and Nanog compared with controls on day 4, but 
not as much as nicotinamide (Fig. 10B). Similarly, 3-aminobenzamide significantly 
increased levels of Lhx2 and Rax compared with controls on day 4, but not as much as 
nicotinamide (Fig. 10B). Overall, 3-aminobenzamide was able to partially recapitulate the 
effects of nicotinamide. 
 
Activin A, SU5402, and VIP Direct Early Eye Field Cells to an RPE Fate 
Following the acquisition of early eye field markers by day 4 (Fig. 10B), we sought to 
direct the cell to RPE instead of neural retina. With this in mind, we phased out the addition 
of nicotinamide (added days 0 – 4), Noggin (added days 0 – 4), bFGF (added days 2–4), 
IGF1 (added days 0–6), and Dkk1 (added days 0–6) and tested the effect of Activin A, 
SU5402, and VIP on RPE specification.  
The addition of Activin A on days 4–10 had little effect on gene expression of Mitf, a 
marker of the optic vesicle and of RPE. Expression of Rax, a marker of the early eye field 
and neural retina, was significantly decreased (Fig. 10D). Addition of SU5402 on days 6 –10 
had little effect on expression of either Mitf or Rax; however, in combination with Activin 
A, expression of Rax was further decreased (Fig. 10D). VIP has been previously shown to 
speed up maturation of cultured primary RPE by increasing intra- cellular cAMP and 
activating pp60(c-src) [22]. Addition of VIP on days 6–10 significantly increased  
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Figure 10. Defined factors rapidly direct pluripotent cells toward an early eye field and retinal 
pigmented epithelium fate. (A): Timing of factor addition. The factors in red were under 
investigation. (B): The effect of nicotinamide and 3-aminobenzamide on pluripotency and early eye 
field gene expression. mRNA levels were quantified by polymerase chain reaction (qPCR) and 
normalized to the control condition (IGF1, Noggin, DKK1, and bFGF at the times shown in [A]). 
The error bars represent the standard error of the mean. *, p < .1. (C): The effect of nicotinamide on 
cell morphology. Phase contrast images are shown. Scale bars = 200 µm. (D): The effect of Activin 
A and SU5402 alone and in combination on Mitf and Rax gene expression. mRNA levels were 
quantified by qPCR and normalized to the control condition (IGF1, Noggin, DKK1, bFGF, and 
nicotinamide at the times shown in [A]). The error bars represent the standard error of the mean. (E): 
The effect of VIP on retinal pigmented epithelium gene expression. mRNA levels were quantified by 
qPCR and normalized to the control condition (IGF1, Noggin, DKK1, bFGF, nicotinamide, Activin 
A, and SU5402 at the times shown in [A]). The error bars represent the standard error of the mean. 
**, p < .05. (F): Morphology at day 10 following the addition of IGF1, Noggin, DKK1, bFGF, 
nicotinamide, Activin A, SU5402, and VIP at the times shown in (A). The asterisk marks an area 
with cobblestone morphology. Scale bar = 200 µm. Abbreviations: bFGF, basic fibroblast growth 
factor; IGF, insulin-like growth factor; VIP, vasoactive intestinal peptide. 
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expression of RPE marker genes Mitf, tyrosinase, and PEDF (Fig. 10E). Consistent with the 
roles of Mitf and tyrosinase in pigment synthesis, pigmentation was increased in cultures 
containing VIP between days 10 and 14 (data not shown). By day 10, sheets of cells with 
cobblestone morphology and distinct borders were visible (Fig. 10F; supplemental Fig. 6A, 
6B). 
 
Differentiation to RPE Is Highly Efficient 
Following 4 more days in culture with Activin A, SU5402, and VIP, the borders of 
cobblestone sheets became more defined, and some cells began to pigment (Fig. 11A; 
supplemental Fig. 6A, 6B). Immunocytochemistry for the melanosomal protein Pmel17 
(upon which melanin pigment is deposited) exclusively labeled these pigmenting sheets of 
cells (Fig. 11A). Quantitative polymerase chain reaction (qPCR) analysis showed that com- 
pared with cells differentiated in B27/N2 containing basal medium only (no factor 
differentiation), cells that had been exposed to RPE differentiation factors (nicotinamide, 
IGF1, DKK1, Noggin, bFGF, Activin A, SU5402, and VIP) had significantly increased lev- 
els of the RPE marker genes Mitf, Tyrosinase, Tyrp2, PEDF, BEST1, and Pmel17 (Fig. 
11B). Additional immunocytochemistry revealed Mitf expression exclusively in pigmenting 
sheets of cells, whereas Lhx2 and ZO1 could be found in both pigmenting sheets and non-
RPE cells (Fig. 11C). Interestingly, in addition to Lhx2, some non-RPE cells expressed Oct4 
(Fig. 12B). When isolated and replated in pluripotent stem cell conditions, these cells did not 
form colonies with typical undifferentiated stem cell morphology, and many appeared to 
differentiate into neurons (supplemental Fig. 6C). 
 To determine the efficiency of differentiation, we performed flow cytometry using the 
Pmel17 antibody, which is highly sen- sitive and which labels only pigmenting sheets of  
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Figure 11. Sheets of RPE progenitors are efficiently generated and begin to pigment by 
day 14 of differentiation. (A): Bright field and immunofluorescence images of a sheet of 
RPE at day 14. The arrow points to pigmented cells. Scale bars = 500 µm. (B): RPE gene 
expression following differentiation in insulin-like growth factor 1, Noggin, DKK1, basic 
fibroblast growth factor, nicotinamide, Activin A, SU5402, and vasoactive intestinal peptide 
compared with differentiation in basal medium alone. mRNA levels were quantified by 
quantitative polymerase chain reaction and normalized to the no factor condition 
(differentiated in B27/N2 DMEM/F12 medium). The error bars represent the standard error 
of the mean. *, p < .1; **, p < .05. (C): Immunofluorescence images of RPE sheets at day 
14. Scale bar = 100 µm. (D): Quantification of Pmel17 and Oct4 immunoreactivity by flow 
cytometry after 14 days differentiation of H9, UCSF4, and IMR90, compared with 
undifferentiated H9. The error bars represent the standard error of the mean. **, p < .05. (E): 
Representative flow cytometry histograms for Pmel17 and Oct4 at day 14 (H9-RPE, H9 no 
factor differentiation), undifferentiated H9 cells, MeWo cells (positive control for Pmel17), 
and Hs27 cells (negative control for both Pmel17 and Oct4). Abbreviations: Ctrl, control; 
RPE, retinal pigmented epithelium. 
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Figure 12. Gene expression, protein expression and flow cytometry histograms for cells 
differentiated from additional pluripotent cells lines on day 14. (A) qPCR analysis of RPE 
marker genes at day 14. Expression is normalized to expression of a panel of housekeeping 
genes; error bars represent standard error of the mean. (B) Immunofluorescence images of 
RPE and pluripotency markers. Scale bars = 50µm. (C) Representative Oct4 and pmel17 
flow cytometry histograms. 
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cells by immunocytochemistry. We also examined the loss of the pluripotency marker Oct4 
by flow cytometry. We found that H9 cells could be differentiated into Pmel17+ cells by day 
14 with an average efficiency of 78.5% (+1.2%, n = 6, H9-RPE) (Fig. 11D). This was highly 
significant when compared with either undifferentiated H9 cells (12.8% + 2.4%, n = 3, H9) 
or cells differentiated in basal medium alone (25.2% +1.6%, n = 3, no factor differentiation) 
(Fig. 11D). We tested the differentiation protocol on two additional pluripotent stem cell 
lines: the embryonic stem cell line UCSF4 and the induced pluripotent stem cell line 
IMR904. The UCSF4 line yielded Pmel17+ cells with an efficiency similar to H9 cells 
(79.8% + 0.88%, n = 3, UCSF4-RPE), whereas the IMR904 line was slightly less efficient 
(63% + 0.88%, n = 3, IMR904-RPE) (Fig. 11D). The percentage of Oct4+ cells was less than 
5% in all conditions except undifferentiated H9 cells (98.1% + 0.6%, n = 3, H9) (Fig. 11D). 
Examination of representative flow cytometry histograms reveals population expression 
levels of Pmel17 and Oct4 protein on day 14. We compared H9-RPE cells differentiated in 
basal media (no factor differentiation), undifferentiated H9 cells, the melanocyte cell line 
MeWo (a positive control for Pmel17), and the fibroblast line Hs27 (a negative control for 
both Oct4 and Pmel17). Interestingly, undifferentiated H9 cells appeared to express low 
levels of Pmel17 (Fig. 11E). This is consistent with findings in our own lab and others that 
undifferentiated stem cells express low levels of this transcript [11, 23]. A high level of 
Pmel17 protein expression was only seen in H9-RPE cells and the positive control MeWo 
cells (melanocytes) (Fig. 11E). 
Interestingly, cells left in culture past day 14 with Activin A, SU5402, and VIP led to 
death of non-RPE cells (supplemental Fig. 6A, 6B). This suggests that the culture conditions 
are both directive and selective for RPE. Because one of our goals was to determine the 
earliest time we could generate homoge-nous cultures of RPE, we focused on day 14 as the 
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end point of directed differentiation.  
Protein and mRNA Time Courses Reveal Stages of RPE Development 
To better understand the nature of our differentiation protocol, we analyzed both protein 
and mRNA expression of a panel of genes over 14 days of differentiation. As expected, 
pluripotency gene and protein expression (Oct4 and Nanog) decreased rapidly over the first 
4 days (Fig. 13A, 13B). Interestingly, Oct4 and Nanog expression increased slightly 
between days 4 and 6, during which time Activin A was added to the protocol (Fig. 13B). 
Early neural and eye field markers (Lhx2, Pax6(-5a), Pax6(-5a), and Rax) were expressed as 
early as day 2, with expression increasing throughout the 14-day time period with the 
exception of Rax (Fig. 13A, 13B). Rax expression was transient, increasing from days 2– 6 
and then rapidly decreasing between days 6 and 8 (Fig. 13B). At day 6, IGF1 and DKK1 
were removed from the protocol, whereas SU5402 and VIP were added, which could 
account for the decrease in Rax expression. RPE marker genes were expressed slightly later 
in two phases, between days 4 and 6 (Mitf, PEDF, and BEST1) and between days 6 and 8 
(Pmel17, Tyrosinase, and Tyrp2) (Fig. 13A, 13B). Interestingly, Otx2 mRNA and protein 
were expressed at relatively consistent levels throughout differentiation. 
 
Differentiated Cells Can Be Enriched on Day 14 to Homogenous Cultures of 
Functional RPE 
To generate more homogenous populations of RPE, readily visible sheets on day 14 
were mechanically isolated, dissociated into single cells, and replated in an RPE medium 
[17] on Matrigel-coated tissue culture plastic, chambered slides, or Transwell inserts. 
Surprisingly, RPE enriched on day 14 were sensitive to singe-cell dissociation in the media 
tested, leading to cell death or senescence (supplemental Fig. 6D). Because the Rho- 
associated protein kinase (ROCK) inhibitor Y27632 has been previously shown to support 
single-cell dissociation of epithelial cells [24 –26], including pluripotent stem cells [27], we  
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Figure 13. Differentiating cells rapidly acquire early eye field and retinal pigmented 
epithelium (RPE) marker expression. (A): Immunofluorescence images of pluripotency 
(Oct4), early eye field (Pax6, Lhx2, and Otx2), and RPE (Pax6, Lhx2, Mitf, Otx2, and 
Pmel17) proteins during days 0 –14 of differentiation. Scale bars = 100 µm. (B): 
Quantitative polymerase chain reaction analysis of pluripotency (Oct4 and Nanog), early eye 
field (Lhx2, Pax6(-5a), Pax6(+5a), Rax, and Otx2), and RPE (Lhx2, Pax6(-5a), Pax6(+5a), 
Otx2, Mitf, Pmel17, PEDF, BEST1, Tyrosinase, and Tyrp2) gene expression. Expression is 
normalized to the maximum level of expression over the time period. The error bars 
represent the standard error of the mean. 
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tested the ability of this small molecule to rescue dissociated RPE. The addition of Y27632 
at 10 µM for the first 3 days after passage facilitated RPE survival and maturation (Fig. 14; 
supplemental Fig. 6D). 
After enriching RPE at day 14, we allowed the cells to redifferentiate for 30 days and 
then analyzed gene and protein expression and phagocytosis of rod outer segments. To 
analyze gene expression, hESC-RPE, cultured fetal human RPE (fRPE), and Hs27 
fibroblasts were cultured on Transwell inserts for 30 days. qPCR analysis showed similar 
levels of expression of all RPE marker genes between hESC-RPE and fRPE (Fig. 14A). We 
used Hs27 cells as a negative control for RPE-specific genes; however, we detected some 
Mitf, PEDF, and BEST1 expression in Hs27. Compared with undifferentiated H9 cells, 
expression of Oct4 was ~1,000-fold lower in all other cell lines (Fig. 14A). 
Immunocytochemistry of cells enriched at day 14 and grown on chambered slides for 30 
days showed homogenous populations of RPE based on Mitf, Otx2, Lhx2, ZO1, and Pmel17 
expression (Fig. 14B). Expression of BEST1 and RPE65, markers of more mature RPE, was 
heterogeneous, indicating varying levels of maturity in these cultures (Fig. 14B). Integrin αv 
was localized apically compared with Otx2 nuclear expression, showing proper polarized 
protein trafficking in these cells (Fig. 14B, inset in Integrin αv/Otx2 panel). Although some 
Oct4+ cells were present at day 14 of initial differentiation, no Oct4+ cells were observed 
following enrichment and 30 days of culture (Fig. 14B). 
To determine whether our hESC-RPE were functional, we tested their ability to carry out 
phagocytosis of fluorescently labeled ROSs. Compared with the negative control Hs27 cells, 
hESC-RPE internalized significantly more ROSs (Fig. 14C). This internalization was 
blocked by an antibody against integrin αvβ5, showing that both hESC-RPE and fRPE use 
the same receptor for ROS phagocytosis. hESC-RPE ROS phagocytosis was even greater  
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Figure 14. Analysis of RPE enriched on day 14 and grown for 30 days in culture. (A): 
Quantitative polymerase chain reaction analysis comparing gene expression levels in hESC-
RPE to cultured fetal human RPE as a positive control and Hs27 cells as a negative control. 
Undifferentiated H9 cells are included as a positive control for Oct4 expression in the first 
panel. Expression is normalized to a panel of housekeeping genes. The error bars represent 
the standard error of the mean. (B): Bright field and immunofluorescent labeling of RPE and 
pluripotency markers. The inset in the Integrin αv/Otx2 panel shows the confocal z-stack 
cross-section. Scale bars = 50 µm. (C): Internalization of fluorescently labeled ROSs 
quantified by integrated pixel density analysis of fluorescent images. The error bars 
represent the standard error of the mean. *, p < .05; **, p < .01 versus respective Hs27 
control and corresponding anti-αvβ5 condition. Abbreviations: anti-αvβ5, function blocking 
integrin αvβ5 antibody; fRPE, fetal human retinal pigmented epithelium; hESC, human 
embryonic stem cell; Iso-Ctrl, isotype control antibody; RPE, retinal pigmented epithelium; 
ROS, rod outer segment. 
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than that of fRPE, although both RPE lines internalized significantly more ROSs than Hs27 
cells.  
 
Discussion 
The challenge of efficiently directing pluripotent stem cells into a specific lineage has 
progressed rapidly since the derivation of human embryonic stem cells 15 years ago [28, 
29]. Development of efficient protocols to generate RPE, which are the second hESC 
derivative used in clinical trials, has been progressing since initial reports of spontaneous 
differentiation 8 years ago [10, 13, 14, 30]. Here we report a protocol that is both fast and 
efficient. By drawing upon knowledge from developmental biology and other stem cell 
studies, we have optimized timing of factor addition to generate RPE within 14 days. 
Nicotinamide has previously been used to differentiate pluripotent stem cells into RPE 
[13]. It was shown that nicotinamide had an antiapoptotic effect following 2 weeks of 
differentiation, in line with other studies showing neural protection by nicotinamide. Based 
on previous research, it was suggested that this action could be through inhibition of 
poly(ADP-ribose) polymer- ase-1 (PARP1), which was found to regulate cell death upon 
hESC neural induction [21]. In our experiments, the addition of nicotinamide to retinal 
inducing factors IGF1, DKK1, Noggin, and bFGF [15] decreased expression of pluripotency 
genes while concomitantly increasing neural/early eye field genes by day 4. Because it is 
known that the IGF1, DKK1, Noggin, and bFGF protocol induces expression of Lhx2, Rax, 
and Pax6 [15], these gene expression changes suggest that the addition of nicotinamide 
speeds up differentiation. Interestingly, not all neural/early eye field genes were affected by 
nicotinamide. Although Lhx2 and Rax expression increased with nicotinamide addition on 
day 4, Pax6 expression was slightly lower, although this change was not significant. This 
suggests that nicotinamide may not have an effect on Pax6 and may act on a factor 
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downstream. Further studies are needed to elucidate the effect of nicotinamide-expedited 
differentiation on the entire early eye field transcription factor network (Pax6, Lhx2, Rax, 
Six3, Six6, and Tll [31]). We also saw fewer cells in nicotinamide conditions, which could 
result from either cell death or a decrease in proliferation. A decrease in proliferation has 
previously been reported upon exposure of hESCs to nicotinamide [32]. Although these 
results suggest a role for nicotinamide outside of cell survival, we wondered whether 
PARP1 inhibition was still involved. To test the role of PARP1 inhibition in our 
nicotinamide induced differentiation, we tested the ability of another PARP1 inhibitor, 3-
aminobenzamide, to induce differentiation. We found that 3-aminobenzamide could partially 
recapitulate the effects seen with nicotinamide.  Although the exact mechanism of 
nicotinamide-induced neuronal differentiation remains to be elucidated, it is clear that 
nicotinamide can potentiate differentiation, and this potentiation appears to act at least 
partially through PARP inhibition. Neuroprotective/antiapoptotic effects of PARP inhibition 
may also play a role. We find that nicotinamide is a useful tool to speed up initial neural 
differentiation and could potentially be applied to other neural differentiation protocols. 
The addition of Activin A and the FGFR1 inhibitor SU5402 led to only slight increases 
in RPE genes, whereas the early eye field/ neural retina marker Rax was significantly 
downregulated by day 10.  We attribute the former to the potent retinal inducing properties 
of IGF1 [15, 33], whereas the latter confirms the roles of Activin A and FGF signaling in the 
optic vesicle to optic cup stages of eye development. This is seen in both animal and hESC 
models where Activin signaling and FGF inhibition direct the progenitor cells toward RPE 
(Rax-) instead of neural retina (Rax+) [13,16,30]. The addition of VIP significantly increases 
expression of Mitf, Tyrosinase, and PEDF, in agreement with results found in primary 
cultures of RPE [22]. Although we continued to use VIP for these experiments and indeed 
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saw an increase in pigmentation at earlier time points, the use of VIP at 1 µM can be quite 
expensive. For practical purposes, VIP can be left out of the protocol. 
By day 14 of differentiation, sheets of RPE can clearly be seen with defined borders that 
express several RPE marker genes and proteins. By this time cells have begun to pigment. 
Interestingly, the speed of pigmentation appears to be inversely correlated with the 
efficiency of RPE differentiation or size of the RPE sheet (data not shown). Small sheets 
(<500 µm) tended to pigment faster than large sheets (>5 mm). This suggests that signals 
coming from non-RPE cells may have a positive effect on pigmentation. Future studies will 
be necessary to determine what those signals may be. 
Generation of RPE from both H9 and UCSF4 embryonic stem cell lines was highly 
efficient, averaging close to 80% based on Pmel17 immunoreactivity. This method induced 
efficient differentiation of RPE in the UCSF4 cell line, which is resistant to RPE 
differentiation using the spontaneous method (data not shown). The efficiency of RPE 
generation from IMR904 induced pluripotent stem (iPS) cells was somewhat less efficient at 
60%. The cause of this difference in efficiency is unclear, although it could be due to 
incomplete silencing of the reprogramming transgenes. It will be interesting to see whether 
the efficiency is consistently lower in iPS cells compared with embryonic stem cells, 
although we do not suspect this to be the case. 
Cells that did not express Pmel17 on day 14 of differentiation expressed Oct4 and Lhx2. 
When isolated on day 14 and placed back in embryonic stem cell conditions, these cells did 
not form colonies that resembled embryonic stem cell morphology, and many appeared to 
differentiate into neurons. We suspect that these cells may be stuck in a partially 
differentiated state. If differentiating cultures were kept longer than 14 days, these non-RPE 
cells began to die. We therefore consider the Activin A-, SU5402-, and VIP-supplemented 
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medium to both direct differentiation and select for RPE over non-RPE cells, leading to 
virtually homogenous populations of RPE after 3 weeks. 
Analysis of gene and protein expression throughout the 14-day differentiation period 
revealed several interesting trends. First, as expected, early neural and eye field genes were 
expressed first, followed by later markers of the optic vesicle and RPE [16]. Interestingly, 
although gene expression followed the known developmental sequence, transition from early 
eye field to optic vesicle and RPE was quite rapid. This suggests that during normal 
development, the ability of a cell to respond to developmental cues can precede those signals 
by a significant amount of time, perhaps to allow time for tissue growth. Between days 4 
and 6, a slight increase in Oct4 and Nanog gene expression was observed. We believe this is 
likely because of the addition of Activin A on day 4 because Activin A signaling has been 
shown to maintain pluripotency [34 –36]. Consistent with recent observations in Rax-GFP 
pluripotent stem cells undergoing ocular morphogenesis [37, 38], we saw transient 
expression of Rax between days 2 and 8. This would appear to correspond with expression 
in the early eye field followed by down-regulation in the RPE. Interestingly, Otx2, which 
has been shown to be repressed by Rax specifically in the early eye field of Xenopus [31], 
maintained a fairly consistent level of both mRNA and protein expression over the 14-day 
time course. In fact, Otx2 mRNA expression increased when Rax mRNA expression was at 
its highest. These observations, along with results from other hESC retinal differentiation 
protocols [30], suggest that Otx2 is expressed in the early eye field of humans. Alternatively, 
there are two known protein isoforms of Otx2 in humans and several different transcripts, 
which may be alternatively regulated. Our experiments do not differentiate between these 
isoforms. There is also the possibility that maintained Otx2 expression throughout ocular 
differentiation may be an artifact of cell culture and may not be found in vivo. 
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 Because morphologically distinct sheets of RPE became visible between days 10 and 
14, we tried to isolate cells at these early time points. Initial attempts were unsuccessful; 
however, with the addition of the ROCK inhibitor Y27632 over the first few days of culture, 
RPE could be enriched at both of these time points and would mature into functional RPE 
when replated. The borders of RPE sheets at day 10 were harder to distinguish, which made 
enrichment to homogenous populations difficult; therefore we focused on enrichment at day 
14. Tight junctions among non-RPE cells made them easy to remove as sheets by dragging a 
pipette tip along borders with RPE. 
ROCK inhibition has been used successfully to maintain survival of hESCs dissociated 
into single cells as well as to enhance proliferation of certain epithelial cell types [24 –27]. 
The mechanism of ROCK inhibition has been worked out in hESCs, where ROCK mediates 
E-cadherin cell adhesion sensing [39]. The mechanism of ROCK inhibition in proliferation 
of other epithelial cell types, including in our own system, remains to be elucidated. Primary 
RPE cultures, when dissociated into single cells over several passages, lose their ability to 
redifferentiate into mature RPE and become fibroblastic in morphology. This may be a 
wound response for an epithelium that does not normally exist as single cells and may be 
similar to the effect we see following single-cell dissociation on day 14 of differentiation. 
Additionally, our selection of basal medium may not be optimal for proliferating cultures of 
RPE enriched at day 14. We are currently testing novel medium compositions, some of 
which support single-cell growth even in the absence of ROCK inhibitor. Although the 
mechanism is not known, enrichment of RPE cells on day 14 in the presence of ROCK 
inhibitor can generate homogenous populations that express RPE marker genes at similar 
levels to cultured fetal human RPE, express proper RPE proteins, are polarized, and display 
integrin αvβ5-dependent phagocytosis of rod outer segments. 
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Conclusion 
This protocol should be useful for studying human ocular differentiation within a shorter 
time period than in vivo development. Signals that specify melanogenesis in RPE are still 
under investigation. Our observation that cultures with more non-RPE cells led to faster 
RPE pigmentation suggests that these cells may secrete factors that activate melanogenesis. 
Analysis of the proteome of these non-RPE cells may lead to identification of melanogenic 
factors. This protocol will also be useful for rapidly generating banks of RPE for the 
treatment of age-related macular degeneration and other disorders of the RPE. 
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B. Xeno-Free Adaptation of Rapid and Efficient Directed Differentiation 
 
Britney O. Pennington 
 
Abstract 
Age-related macular degeneration (AMD) is the leading cause of blindness in people 
over 65 years of age, and it is caused by the dysfunction of the retinal pigmented epithelium 
(RPE).  Transplantable therapies consisting of human embryonic stem cell derived-RPE 
(hESC-RPE) are currently under development.  However, production of hESC-RPE can be 
very time intensive, therefore several directed differentiation protocols have been 
established.  The most rapid protocol to date generates hESC-RPE in 14 days (D14 protocol) 
but utilizes animal derivatives throughout the process.  In order to generate hESC-RPE for 
cellular therapies, defined reagents compliant with good manufacturing practices (GMP) 
must be used.  This chapter describes the preliminary work to qualify xeno-free substitutes 
for the components of the D14 protocol.  These data demonstrate that Matrigel® can be 
replaced with the synthetic substrate Synthemax®II-SC and that the defined small molecule 
DMH1, a specific BMP inhibitor, can replace recombinant mouse Noggin during the D14 
protocol.  This chapter also presents results of a pilot study employing dual-Smad inhibition 
with DMH1 and SB431542 that effectively replaces the recombinant growth factors 
msNoggin, Dkk-1, IGF-1 and bFGF to generate a cell population expressing PMEL17, a 
pigmented cell marker, in 14 days.  Further research is needed to confirm the RPE identity 
of these cells and to identify defined alternatives to the remaining two growth factors in the 
D14 protocol.  A rapid and efficient xeno-free protocol for generating hESC-RPE would 
contribute a tremendous advantage to the cost-effective production of cellular therapies for 
AMD. 
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Introduction 
Age-related macular degeneration (AMD) is a debilitating blinding disease affecting 
the elderly and is caused by the dysfunction and death of the retinal pigmented epithelium 
(RPE).  Although therapies utilizing human embryonic stem cell-derived RPE (hESC-RPE) 
are under development, the production of the therapeutic cells can be exceedingly time 
intensive.  Spontaneous differentiation of hESCs into RPE requires several months and the 
efficiency can vary greatly.  Therefore, many directed differentiation protocols that 
accelerate the rate of differentiation and increase final yield of RPE have been explored [1-
4].  We have recently developed the most rapid protocol to date, one that promotes RPE cell 
differentiation from stem cells in just 14 days.  Up to 80% of these cells expressing 
PMEL17, a protein necessary for the deposition of melanin granules in the melanosomes of 
pigmented cells [5, 6].  However, this “D14” protocol utilizes animal-derived products and 
recombinant proteins.  These components represent a challenge to develop these cells as 
therapies due to the risk of exposure to non-human immunogens, which may affect patients 
post-transplantation.  In order to convert the D14 protocol into a xeno-free procedure, 
synthetic, animal-derived component-free (ACF) replacements must be found for each 
constituent. 
The D14 protocol utilizes Matrigel®, a substrate rich in extracellular matrix proteins 
derived from the Engelbreth-Holm-Swarm murine sarcoma [7].   Synthemax®II-SC 
Substrate, is a novel, ACF peptide-copolymer that we have demonstrated to support hESC 
differentiation into functional RPE (Pennington et al. submitted).  hESC-RPE differentiated 
on Synthemax®II-SC were similar to those on Matrigel® in gene expression and function.  
This suggests that Synthemax®II-SC may also be a viable alternative to Matrigel® for 
directed differentiation under xeno-free conditions.  
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The original D14 protocol employs recombinant mouse Noggin (msNoggin), as well 
as other recombinant human proteins.  Full-length recombinant proteins are prone to batch-
to-batch variation and can raise production costs [8, 9], which may hinder large-scale 
production of therapeutic hESC-RPE.  Therefore, synthetic small molecule replacements for 
the original D14 growth factors must be investigated.  The original D14 protocol emulates 
two distinct differentiation steps: the first establishes neural induction and the second 
establishes RPE identity.  A primary aim was to identify a small molecule alternative as a 
replacement for msNoggin in the neural induction step.   
 Noggin protein is a secreted homodimer [10] that has a high binding affinity for 
BMP2 and BMP4 and can inhibit the bone morphogenetic protein (BMP) branch of the 
TGFβ superfamily signaling pathway, which consists of BMPs, growth/differentiation 
factors (GDF) and anti-Müllerian hormones (AMH) [11].  Soluble BMP dimers associate 
with Type I receptor dimers via hydrophobic interactions [12].  The ligand-receptor complex 
recruits Type II receptor dimers which become constitutively active and phosphorylate the 
Type I receptor [13].  Both receptor types are serine/threonine kinases; upon activation, the 
Type I receptor phosphorylates a receptor-regulated Smad, which promotes Smad 
association with co-Smad4. The Smad heterocomplex translocates into the nucleus to 
regulate the expression of genes that modulate growth and differentiation [12-14].   Noggin 
bindins and prevents BMP4 from associating with its receptor, and this inhibition is 
necessary for neural induction [11].   
Synthetic small molecule alternatives to noggin could antagonize any component in the 
pathway.  BMP4 associates with Type I activin receptor-like kinase (ALK)-3 to 
phosphorylate downstream Smads1/5/8 [15].   Small molecule antagonists to BMP-specific 
ALKs have been developed.  The first small molecule inhibitor was identified through a 
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phenotypic screen of small molecules that promoted dorsalization in zebrafish embryos.  
Compound C, a known inhibitor of AMPK, was renamed Dorsomorphin as it stimulated 
dorsalization during zebrafish development by inhibiting ALK2, ALK3 and ALK6 [16].   Its 
derivative, LDN-193189 has increased effectiveness in inhibiting the BMP receptors [14].  
However, these two small compounds also have high inhibitory activity against many off-
target proteins such as VEGF, AMPK and FGF-R than the desired ALKs [13].   To improve 
specificity, a structure-activity relationship study in zebrafish using analogues of 
dorsomorphin was used to identify the small molecule DMH1, which is a highly specific 
inhibitor of ALK2 and ALK3 and can effectively inhibit the phosphorylation of Smads1/5/8 
(IC50 < 0.2µM) [17].  Therefore, DMH1 is a viable, xeno-free candidate to replace 
msNoggin during the D14 directed differentiation. 
 The BMP/GDF/AMH subfamily is not the only branch of the TGFβ pathway that can 
suppress neural differentiation however.   The Nodal/Activin/TGFβ subfamily has also been 
implicated in impeding development of the neuroectoderm while promoting the mesoderm 
and endoderm lineages [18].  For example, Nodal knockout mice have enhanced 
neuralization [19] and Activin-A promotes hESCs to differentiate into definitive endoderm 
[20].  Furthermore, Nodal and Activin-A can also sustain the pluripotent state of hESCs [21, 
22].  Therefore, in order to encourage hESC differentiation towards an anterior 
neuroectoderm lineage, signaling by the Nodal/Activin/TGFβ subfamily should also be 
targeted.   This branch of soluble ligands first binds to Type II receptors which recruit the 
Type I receptors (ALK4, ALK5, and ALK7) to mediate intracellular signaling by Smad2/3 
phosphorylation [12, 13].  SB431542 is a small molecule that competitively binds to the 
ATP-binding site on ALK4/5/7 and acts as a highly specific inhibitor with an IC50 < 0.2µM 
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for each receptor [23].   In the presence of other compounds, SB431542 can augment the 
neural differentiation of hESCs but is insufficient to do so alone [24].   
A more effective approach to promote neural induction is to simultaneously antagonize 
both the Nodal/Activin/TGFβ and the BMP/GDF/AMH branches of the TGFβ superfamily, 
known as dual-Smad inhibition and was first explored in 2009 [24].  Accomplishing dual-
Smad inhibition with Noggin and SB431542 directs hESCs and iPSCs to differentiate into 
neural precursor populations with rosette morphologies that are positive for Pax6, an early 
neural marker essential for ocular development, and these cells can further be directed into 
dopaminergic neurons and motorneurons [24, 25].  Performing dual-Smad inhibition with 
LDN-193189 and SB431542 has been shown to promote differentiation of human 
pluripotent stem cells into nociceptors of the peripheral nervous system [26], but LDN-
193189 has also been shown to have numerous off-target effects [13].   Combining the 
BMP-specific inhibitor DMH1 and SB431542 during differentiation of hiPSCs recapitulated 
the decrease in Oct4 and Nanog expression and an increase in Pax6 transcripts observed in 
cells exposed to Noggin and SB431542.  Furthermore, the neural precursors produced solely 
by the two small molecules were competent to further differentiate into dopaminergic 
neurons [27].  This study by Neely et al. demonstrated that dual-Smad inhibition by DMH1 
and SB431542 is sufficient to induce a neural population during differentiation of 
pluripotent stem cells.  This indicates that DMH1 and SB431542 may be viable alternatives 
to recombinant growth factors during the neural induction step of the D14 directed 
differentiation protocol. 
The ultimate goal of these studies is to replace all of the original D14 growth factors 
with small molecules.  This chapter describes the initial steps taken to optimize a xeno-free 
D14 protocol and presents data showing that Synthemax®II-SC can replace Matrigel® and 
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that the xeno-free small molecules DMH1 and SB431542 can replace msNoggin, Dkk1, 
IGF1, and bFGF to accomplish neural induction in the D14 protocol to yield cells positive 
for PMEL17 in two weeks. 
 
Materials and Methods 
hESC culture 
H9 hESCs at passages 62-64 (on Synthemax®II-SC for 25-27 passages) were grown on 
Synthemax®II-SC coated vessels (5 µg/cm2) (Corning #3536-XX1) in mTeSR™1 stem cell 
medium (STEMCELL Technologies, #05850) and passaged by manual dissection for hESC 
maintenance.   
 
Synthemax®II-SC Substrate Vessel Coating 
Tissue culture vessels were coated with Synthemax®II-SC according to the 
manufacturer’s recommendations for routine hESC culture.  Briefly, Synthemax®II-SC 
powder was resuspended to 1 mg/mL in HyClone HyPure Cell Culture Grade Water 
(AWK21536) and stored at 4°C for 1 month or further diluted 1:40 (0.025 mg/mL). Tissue 
culture vessels for hESC culture were coated at a density of 5 µg/cm2, and 12 well tissue 
culture plates for differentiation were coated at a density of 2.6 µg/cm2 for 2 hours at room 
temperature.  Synthemax®II-SC solution was aspirated and the air-dried vessels were used 
immediately or stored at 4°C for up to 3 months. 
 
Directed Differentiation 
Differentiation of hESCs into RPE was accomplished with modifications to the original 
D14 protocol previously described [28].  Briefly, hESCs were rinsed 3 times and passaged 
by EDTA dissociation with Versene Solution (Life Technologies, #15040-066) for 8 
minutes at room temperature.  Colonies were resuspended in retinal differentiation medium, 
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RDM (DMEM/F12+GlutaMAX™I, #10565-018; N-2 Supplement, #17502-048; B-27 
Supplement, #17504-044; NEAA, #11140-050; all reagents from Life Technologies) 
supplemented with 10ng/mL recombinant mouse noggin (#1967-NG), 10 ng/mL 
recombinant human IGF-1 (291-G1-200), 10 ng/mL recombinant human Dkk-1 (#5439-DK) 
and 10 mM nicotinamide and were seeded on tissue culture plates coated with 2.6 µg/cm2 of 
Synthemax®II-SC.  This “control” condition was further modified by replacing noggin with 
0.5 µM DMH-1 (Tocris 4126) or by replacing all growth factors with DMH-1 and 10 µM 
SB431542 (Tocris 1614).  For the control condition, 5ng/mL of bFGF was added on Day 2.  
For all conditions on Day 4, nicotinamide was removed from the media and 100ng/mL 
Activin-A (PeproTech #120-14E) was added.  On Day 6, all RDM media was only 
supplemented with Activin-A, 1 µM VIP (Sigma V6130), and 10 µM SU5402 (EMD 
Millipore 572630-500UG) until Day 14.  
 
Flow Cytometry 
On Day 14, wells were washed with warm DPBS, dissociated with TrypLE Select for 7 
minutes at 37°C and diluted 1:5 in fresh RDM.  Cells were pelleted at 1000 rpm for 3 
minutes, rinsed in 0.5% BSA Fraction V (Gibco #15260-037) in PBS, and pellets were fixed 
in 4.0% paraformaldehyde (Electron Microscopy Sciences #15710) for 10 minutes at room 
temperature in the dark.  Cells were pelleted at 2300 rpm for 3 minutes and permeabilized 
with 0.2% Triton-X (Roche 11332481001), 0.1% BSA Fraction V in PBS for 3 minutes at 
room temperature.  Fixed cells were stored at 4°C in 0.5% BSA until staining.   
 Cells were stained with primary antibodies diluted with 3% BSA in PBS for 40 
minutes at room temperature (HMB45 (PMEL17), 0.1 µg/ml Dako M0634; Mouse IgG1 
isotype control, Dako X0931).  Samples were stained with a secondary antibody for 30 
minutes at room temperature (AlexaFluor® 488, Life Technologies A21202).  Cells were 
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rinsed with 0.5% BSA in PBS and data were collected on a BD Accuri®C6 Flow Cytometer 
with 10,000 gated events per sample.  Gates were set to exclude 99.0% of the population 
stained with the isotype control of the primary antibody.  Data was analyzed with FCS 
Express (De Novo Software). 
 
Quantitative Polymerase Chain Reaction 
On Day 14, 1.5x105 cells were collected with TrypLE Select and processed with the 
Cells-to-Ct kit (Ambion #4399002).  Real-time qPCR was completed with TaqMan Gene 
Expression Assays (Life Technologies #4351372) in TaqMan Gene Expression Master Mix 
(Life Technologies # 4369016) using a Bio-Rad CFX96™Real-Time System.   Data were 
analyzed with the Bio-Rad CFX Manager software and expression was normalized to 
housekeeping genes. 
 
Results 
A Decrease in the concentrations of msNoggin and Synthemax®II-SC is required to 
eliminate Matrigel® from the D14 Protocol.  
 
The first step in adapting the D14 protocol to a xeno-free procedure aimed to replace 
Matrigel® with the ACF peptide copolymer, Synthemax®II-SC.  However, direct 
substitution of Synthemax®II-SC at its recommended concentration (5µg/cm2) for Matrigel® 
resulted in a low yield of cells that expressed PMEL17 by day 14 (data not shown).  Instead, 
three-dimensional aggregates developed during the directed differentiation phase.  Neural 
rosette morphology appeared by day 4 of differentiation in these cultures (Fig. 15A).  The 
original D14 differentiation protocol yields a monolayer of cells with the majority 
expressing PMEL17 by day 14.  At day 14 on Synthemax®II-SC however, the most 
prevalent morphology was thick clusters of neural rosettes and only ~12% of the cells 
expressed PMEL17 (Fig. 15A, flow data not shown).  Although RPE arise from the neural 
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ectoderm, the greater than normal neural differentiation exhibited by these cultures 
suggested that the inductive signals should be decreased. 
Since noggin is a primary neural inducer [29], concentrations lower than the original 50 
ng/mL were tested (0, 5, and 10 ng/mL).  A slight increase in the number of regions 
containing cellular monolayers appeared by day 14 compared to the 50ng/mL noggin control 
cultures, but the majority of each condition still consisted of thick, three-dimensional 
aggregates with neural rosettes.  We hypothesized that the concentration of substrate was too 
dense to allow sufficient cellular migration, which may have contributed to the formation of 
thick cellular clumps.  Therefore, the original D14 protocol was conducted on dilutions of 
Synthemax®II-SC (2.6, 1.0 and 0.5 µg/cm2) in the presence of 50ng/mL msNoggin.  
However, each condition still developed neural rosettes, despite the reduced substrate 
concentrations (data not shown).   
Since individually diluting msNoggin or Synthemax®II-SC only yielded a very small 
population of cells positive for PMEL17, combined dilutions of msNoggin and 
Synthemax®II-SC were tested.  The condition of 10 ng/mL msNoggin for the first four days 
of directed differentiation on tissue culture vessels coated with Synthemax®II-SC at a 
density of 2.6 µg/cm2 yielded a cellular monolayer with defined regions of RPE sheets by 
day 14 (Fig. 15B).  Half of the culture was positive for PMEL17 as detected by flow 
cytometry (Fig. 15B).  When the initial seeding density was doubled, the majority of the 
culture produced by day 14 was a monolayer of RPE, and 80% of the cells were positive for 
PMEL17 (Fig. 15B).  In summary, the simultaneous dilution of msNoggin and 
Synthemax®II-SC concentrations was required to eliminate Matrigel® from the D14 
protocol.  This demonstrates that a xeno-free substrate is compatible with the rapid 
derivation of hESC-RPE. 
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Figure 15:  Altering concentrations of msNoggin and Synthemax®II-SC allows elimination of 
Matrigel® from the D14 protocol.  (A) Replacing Matrigel® with Synthemax®II-SC in the 
original D14 protocol yields thick aggregates of cells that promote formation of neural rosettes.  
The original D14 protocol yields a monolayer of RPE cells after two weeks while thicker neural 
clusters are observed on Synthemax®II-SC.  (B) Altering the concentration of the neural 
inducing growth factor, msNoggin, and decreasing the peptide density of Synthemax®II-SC 
markedly increases the yield of cells positive for PMEL17 by day 14. Top: Areas of lighter, non-
RPE cells are outlined in the bright field images of cells differentiated for 14 days with 10ng/mL 
msNoggin on Synthemax®II-SC (2.6 µg/cm2).  Right: Doubling the initial seeding density prior 
to differentiation notably increased the yield of cells positive for PMEL17.  Bottom: Flow 
cytometry histograms representing the yield of cells positive for PMEL17 in each condition after 
14 days of directed differentiation with modified concentrations of msNoggin and 
Synthemax®II-SC.  (A,B) Scale bar = 200µm. 
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Replacing animal-derived products in the D14 differentiation protocol with Xeno-Free 
alternatives 
 
The next goal was to eliminate recombinant msNoggin from the modified D14 
protocol using Synthemax®II-SC.  Noggin is a secreted protein that directly binds to the 
soluble BMP ligand to prevent its association with ALK3 to inhibit signaling.  Previous 
studies have shown that DMH1, a synthetic small molecule, specifically inhibits ALK2 and 
ALK3 and mimics the effects of noggin [17, 27].  Replacing msNoggin with 0.5µM DMH1 
recapitulated the formation of RPE sheets after 14 days of directed differentiation (Fig. 
16A).  Furthermore, 75% of the cells were positive for PMEL17 after replacing msNoggin 
with DMH1 (Fig. 16B).  Cells generated by either msNoggin or DMH1 displayed similar 
gene expression levels for the pigmentation marker Silv (PMEL17), Mitf isoforms and 
somewhat reduced expression of the RPE chloride channel, Best 1 (Fig. 17).   Importantly, 
neither condition produced cells positive for Mitf isoform 4, which is indicative of 
melanocytes and not RPE. 
The next goal aimed to eliminate the remaining recombinant growth factors during 
the neural induction step in the D14 protocol using dual-Smad inhibition.  In the original 
D14 protocol, this step is accomplished within the first four days, resulting in neural 
morphology (Fig. 18A) and the expression of early eye field transcription factors Otx2, 
Lhx2, Rax and Pax6 [28].  However, according to a previously published report, Otx2 and 
Pax6 expression does not become up-regulated by DMH1 and SB431542 until the fifth or 
seventh day, depending on the iPSC line [27].  Therefore, dual-Smad inhibitors were applied 
for either the first 4 or 6 days of the modified D14 protocol on Synthemax®II-SC.  At day 4, 
hESCs undergoing neuralization by DMH1 and SB431542 manifested a different 
morphology than cells generated by the original D14 method (Fig. 18B).  Cells exposed to 
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the small molecules until day 6 however, displayed the typical neural phenotype (Fig. 18C).  
After neural induction for either four or six days, Activin-A, vasoactive intestinal peptide 
(VIP) and SU5402, an FGF inhibitor, were added until day 14 to establish an RPE identity.   
Interestingly, ~80% of the cells in both conditions were positive for PMEL17.  These 
preliminary findings suggest that dual-Smad inhibition by DMH1 and SB431542 may be a 
viable alternative to recombinant growth factors during the initial phase of the rapid D14 
protocol. 
 
 
 
Figure 16. Replacing msNoggin with DMH1 during D14 yields cells positive for PMEL17.   
Top: Regions of non-RPE are encircled on bright field images after 14 days of 
differentiation on Synthemax®II-SC (Smax2) by using neural induction with (A) 10ng/mL 
msNoggin or (B) 0.5 µM DMH1.  Bottom:  Flow cytometry histograms representing the 
percentage of cells positive for PMEL17 after differentiation on Synthemax®II-SC for 14 
  96 
days with (A) msNoggin or (B) DMH1 during the first four days of directed differentiation.  
Scale bar = 200µm. 
 
 
Figure 17. Replacing msNoggin with DMH1 in the D14 protocol yields cells with similar 
gene expression.  At day 14, cells directly differentiated on Synthemax®II-SC with 
msNoggin or DMH1 have similar gene expression levels for (A) pigmentation markers, (B) 
Mitf isoforms, and (C) the RPE chloride channel Best1.  (B) Note the absence of the 
melanocyte-specific Mitf isoform 4.  
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Figure 18. Achieving neural morphology with small molecules DMH1 and SB431542 
instead of recombinant growth factors during directed differentiation.  A) Cells at day 4 
grown under the original D14 protocol with Matrigel®, recombinant growth factors and 
nicotinamide. Note the neural protrusions at the edges of the colonies.  B) Day 4 of 
differentiation on Synthemax®II-SC with DMH1 and SB431542 just prior to addition of 
Activin-A.  C) Day 6 of a prolonged neural differentiation step on Synthemax®II-SC with 
DMH1 and SB431542 just prior to addition of Activin-A.  D) Cells from (B) at Day 6 after a 
48-hour exposure to Activin-A.  Scale bar = 200µm. 
  98 
 
Figure 19.  Dual-Smad inhibition with DMH1 and SB431542 produces a majority of cells 
positive for PMEL17 by day 14.   Replacing recombinant growth factors with the small 
molecules DMH1 and SB431542 for the first (A) four days or (B) six days of directed 
differentiation yields a majority of cells that express the premelanosome marker PMEL17  
(S2, Synthemax®II-SC; G.F., recombinant growth factors; SB, SB431542). 
 
Discussion  
These studies describe promising xeno-free alternatives to the animal-derived 
substrates and recombinant proteins used for differentiation of stem cells into RPE [28]. 
Ideally, synthetic small molecules would replace all recombinant growth factors during the 
directed differentiation of GMP-grade hESC-RPE.  The preliminary data suggest that 
DMH1 and SB431542 can effectively replace msNoggin, Dkk-1, IGF-1 and bFGF during 
the neural induction step to generate cells positive for PMEL17 by day 14.  However, further 
characterization is required to determine the true identity of these PMEL-positive cells 
produced via small molecules and RPE gene expression and protein localization should be 
determined with additional characterization assays such as immunocytochemistry and 
qPCR.  
Early neural development gives rise to two types of cells that could express 
PMEL17: RPE and neural crest-derived melanocytes, both of which can be generated via 
dual-Smad inhibition.  However, previous studies achieved differentiation of stem cells into 
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neural crest cells only when using low initial seeding densities [24, 26, 30], while higher 
seeding densities yielded cells positive for Pax6 that were capable of differentiating into 
neurons of the central nervous system and RPE [24].  Perhaps this differential outcome can 
be explained by the extent of cell-cell interaction experienced by the cells. During 
neurulation of embryogenesis, the neural plate folds on itself to form the neural groove 
which continues to fold until the edges of the neural plate are juxtaposed and subsequently 
fuse and separate from the overlying ectoderm via preferential homotypic binding of N-
cadherin, thus forming the neural tube [31].  The RPE arise from within the neural plate and 
form tight junctions and interact with adjacent cells [32].  In contrast, neural crest cells arise 
from the margins of the neural plate and are not incorporated within the neural tube.  
Instead, they detach from the neural plate, undergo epithelial to mesenchymal transition 
(EMT), migrate to several distinct destinations in the developing embryo, and give rise to 
multiple cell types such as melanocytes, sympathetic and parasympathetic neurons, carotid 
cells and many others [33, 34].   This may explain the propensity of cells in vitro to adopt a 
neural crest fate if there is opportunity to divide and migrate.  However, the cell-density 
studies generating neural crest cells by dual-Smad inhibition used SB431542 in combination 
with Noggin or LDN-193189, not DMH1.  Additional research is needed to determine if 
DMH1 and SB431542 can feasibly generate neural crest cells.  It will be interesting to 
investigate whether a higher seeding density will facilitate the acquisition RPE identity.  
The second half of the original D14 protocol employs the growth factors Activin-A 
and VIP to direct the neural precursors into RPE. VIP significantly enhances the expression 
of RPE markers, but its addition is not required for producing hESC-RPE within 14 days 
[28].  Further investigation is required to determine the necessity of VIP in the xeno-free 
adaptation of the D14.   
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 The original D14 protocol uses the synergistic effects of nicotinamide and Activin-A 
to increase the yield of pigmented cells from differentiating hESCs.  Activin-A was 
identified as a candidate compound from the extraocular mesenchyme in chicks that induces 
RPE fate [35], and nicotinamide significantly promotes hESC differentiation into pigmented 
RPE [3].   Activin-A has been since used for the directed differentiation of RPE from hESCs 
[3, 4, 36], but it may not be essential.  Free-floating cultures of hESC aggregates 
differentiating in the presence of nicotinamide without Activin-A produced significantly 
more pigmented regions than cultures without either Activin-A or nicotinamde.  
Furthermore, monolayer cultures exposed to nicotinamide and Activin-A increased RPE 
yield, but not when Activin-A was applied alone [3]. Due to the paucity of commercial 
agonists to the TGFβ pathway, especially the Type I ALK4 receptor activated by Activin-A 
signaling, modulating the concentrations of nicotinamide and the duration of its exposure or 
employing GMP-grade human Activin-A may have to suffice in the xeno-free adaption of 
the D14 protocol. 
The results shown here demonstrate a promising, preliminary step towards 
developing a xeno-free protocol for producing hESC-RPE in 14 days.  Further investigation 
is needed to confirm the identity of these cells and to identify alternatives to the remaining 
recombinant growth factors.  Only then will we achieve a true state of Xeno-Freedom.  In 
the long term, these efforst will contirbtue to optimizing hESC-RPE production for use in 
cell therapies for AMD. 
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Abstract: 
We developed an interactive exercise to teach students how to draw the structures of 
the 20 standard amino acids and to identify the one-letter abbreviations by modifying the 
familiar game of “Hangman”.  Amino acid structures were used to represent single letters 
throughout the game.  To provide additional practice in identifying structures, hints to the 
answers were written in “amino acid sentences” for the students to translate.  Students were 
required to draw the structure of the corresponding letter they wished to guess on a 
whiteboard.  Each student received a reference sheet of the structures and abbreviations, but 
was required to draw from memory when guessing a letter.  Pre and post assessments 
revealed a drastic improvement in the students’ ability to recognize and draw structures from 
memory.  This activity provides a fun, educational game to play in biochemistry discussion 
sections or during long incubations in biochemistry labs.  
Keywords:  Interactive Game, Amino Acid Structures, Amino Acid Abbreviations, 
Hangman, Active Learning  
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Introduction: 
Biochemists proclaim that an intimate knowledge of chemical structures contributes 
informative insights into the molecular function and behavior of biochemical processes 
[1,2].  A typical requirement for introductory biochemistry classes is to learn the structure of 
the 20 standard amino acids and the single letter abbreviations.  Students can then reference 
these throughout their academic and professional careers.  Devoting structures to memory 
allows students to immediately recall properties and relative sizes of side chains without 
tediously sorting through mnemonics of which R groups are polar and uncharged or which 
absorb ultraviolet wavelengths, etc.  Once comfortable with the amino acid structures, 
students can apply this knowledge to accomplish higher cognitive tasks such as readily 
explaining the steric and intermolecular consequences of a point mutation in an active site 
and specifically how it affects substrate specificity and enzyme activity without consulting a 
textbook.   
Literacy in the single letter abbreviations is essential for analyzing professional 
protein papers.  The International Union of Pure and Applied Chemistry (IUPAC) and the 
International Union of Biochemistry (IUB) developed a succinct alternative to the 3 letter 
code by establishing the single letter notation to achieve brevity and to compare large 
protein sequences [3,4].  Knowing the corresponding structure when reading the one letter 
code allows students to glean deeper insights into potential interactions or mechanisms.  
Compared to students who are structurally ignorant, for example, informed students can 
readily ascertain the nuances between the biomedically relevant mutations of R406W in tau 
for dementia and Alzheimer’s Disease [5], E6V in hemoglobin for sickle cell anemia [6], 
Y402H in complement factor H for age-related macular degeneration[7] or R117H in cystic 
fibrosis [8].  
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Previous attempts to teach amino acid structure and single letter abbreviations have 
involved complicated rhymes [9],  emphasis on structural similarities to acetyl-CoA, 
pyruvate, and other metabolic intermediates [10], and the rote memorization of nonsensical 
acronyms [2].  Once mastered, these approaches may confer a degree of comprehension, but 
some of these devices may require more tedious studying than just learning the structures 
and abbreviations directly.   
Games have been identified as effective educational tools since the 1920s [11].  
Interactive games have already been developed to teach aspects of protein folding such as 
hands-on activities in the classroom [12] and the online crowd-sourcing sensation, Foldit 
[13].  In the latter, gamers identify novel folding conformations with computational design, 
and many of these proteins have biomedical and renewable fuel applications.  For example, 
the crowd-sourced players identified a new way to fold an alderase to increase its activity 18 
fold [14].  However, these games provide information on the chemical properties of an 
amino acid sequence, and they do not rely on the players’ knowledge of the monomeric 
structures.  To specifically teach the structures and the single letter abbreviations of the 20 
standard amino acids, the modified version of “Hangman” described here employs the three 
primary aspects that make games successful: motivation, practice and reinforcement [15].  
Students are motivated to learn material destined to appear on exams, they practice drawing 
structures during the activity until they can confidently reproduce it in front of an audience, 
and they receive positive reinforcement by solving puzzles and thinking of their own 
Hangman clue(s).  The only mnemonics employed during this game included the simple 
devices developed during the foundation of the single letter code such as pronouncing Asp 
as “aspar-D-ic acid” and Gln as “Q-tamine” [4] as well as an original, baby-like 
pronunciation of Trp as “tWyptophan”.  After playing four rounds of Hangman with amino 
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acid structures instead of English alphabet characters, students exhibited substantial 
improvement in both drawing the structures from memory and correctly labeling given 
structures with the single letter abbreviation. 
Methods 
     Preliminary instructions 
Students were informed during the first biochemistry class of the semester that the 
amino acid structures were cumulative material and would appear on the three exams 
throughout the course.  Three weeks after the announcement, interactive Amino Acid 
Hangman was played in the lab section during the incubation periods of primary and 
secondary antibodies.  The exercise was appropriate for lab sessions due to the relatively 
smaller class sizes compared to lecture and the longer periods of available time.  Students 
were informed that the linear appearance of the “amino acid sentences” were NOT 
indicative of the actual stereochemistry formed by a peptide bond (Fig. 20). 
     Assessment 
In the beginning of the lab session, the instructor announced, “I like science and I 
like having fun and playing games.  Since you will need to know your amino acid structures 
for the exams, we’re going to play a game to help you learn them.  You will also have a 
chance to earn up to 12 points extra credit.” 
Prior to receiving the reference sheet, students took 2 pre-tests.  The first displayed the 
20 single letter abbreviations, and the students were requested to draw the corresponding 
structure.  The second pre-test displayed the 20 structures and the students were instructed to 
assign the correct single letter abbreviations.  The instructions for both pretests were  
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Figure. 20.  Example of the Amino Acid 
Hangman game.   
(a) A hint is drawn in “amino acid sentences” 
(LET’S PLAY A GAME) and spaces 
are drawn for each letter of the 
answer.   
(b) Students guess letters by drawing the 
corresponding amino acid structure.  
If the letter appears in the answer, the 
student redraws the structure in the 
appropriate space(s) indicated by the 
instructor.   
(c) If a proposed structure does not appear in 
the answer, the student redraws it in 
the corner and a body part is added to 
the hangman.  
(d) The puzzle is solved when students draw 
correct structures in all of the 
available spaces. 
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“Drawing/Identifying >10 correct will earn +3 points extra credit.  One wrong answer  
negates any extra credit.”  The latter stipulation aimed to prevent rampant guessing based on 
the idea that grades, even extra points, are precious currency to the students [16]. 
 After the activity, the exact same tests were distributed in the same order with the 
same instructions.  Number of correct answers and structures were quantified. 
Playing the Game 
To play traditional Hangman, one player picks a word or phrase for the audience to 
guess and draws horizontal dashes for each letter in the answer.  The remaining players 
propose letters to fill in the blanks.  If a letter appears within the word, the first player writes 
it in the appropriate spaces.  If an incorrect letter is guessed, one body part is drawn on a 
cartoon gallows.  The object of the game is to guess the word or phrase before a complete 
“hangman” is drawn.  
To play Amino Acid Hangman, students first received a reference sheet with the 
amino acid structures and abbreviations (supplemental Fig. 7) and were allowed to refer to 
this sheet at their lab bench throughout the game.  They were not permitted to bring it to the 
board.  The instructor also wrote hints to the Hangman answers using structures instead of 
English alphabet characters (Fig. 20a, supplemental Table 1).  Audible translation of the hint 
or the answer by a student would negate any extra credit.  To guess a letter, students drew 
the corresponding structure from memory on the whiteboard in front of the class.  If it 
appeared in the answer, the instructor indicated the appropriate space(s), and the student 
redrew the structure as it would appear at pH 7 in order to gain additional practice (Fig. 20b) 
[15].  If filling a space adjacent to a previously drawn amino acid, the student indicated 
which atoms participated in the dehydration reaction of the peptide bond formation, only 
referring to the instructor’s assistance when needed.  If the proposed structure did not appear 
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within the answer however, the student drew it again in the top corner of the whiteboard and 
the instructor added a body part to the Hangman (Fig. 20c).  To avoid discouraging or 
embarrassing the student, the instructor ensured that hands, feet and facial features would 
also be drawn.  “Solving the puzzle” in one attempt was not allowed.  The only way to 
complete the Hangman answer was for volunteers to draw individual structures, which 
maximized the number of participants.  
After each puzzle was solved, the entire section went through the clue together: the 
instructor pointed to each structure and the students responded with the full amino acid 
name.  While the instructor drew the hint for the next round, students were encouraged to 
practice drawing and identifying the amino acids from their reference sheet.  Four rounds of 
Hangman were played in about 2 hours.   
Surprisingly, a few students requested to draw their own hints for their own 
Hangman puzzle.  One student was selected and was allowed to refer to the reference sheet 
while drawing her hint on the board (hint: SCARY SNAKES; answer: VIPERS).  This 
student fulfilled the roles of the instructor for the entire round. 
 
Results and Discussion: 
The post-test revealed a marked improvement in students’ ability to recognize and 
properly label the structures of all 20 amino acids (Fig. 21). Scarcely using a letter in the 
hints or answers did not preclude students from learning the single letter abbreviation.  For 
example, F and V were accurately assigned to the corresponding structure by 41% and 58% 
more students after the activity respectively, despite only being used once during the game.  
Prior to Hangman, not one student correctly drew or identified M, but afterwards, over 40% 
of the class could accomplish both tasks.  Methionine was only used 3 times.  This suggests 
that students consulted the reference sheet with the structures and abbreviations and 
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practiced at their bench while playing the game.  Therefore, the time devoted by the 
instructor to write the “structural sentences” of the next hint can be beneficial to students, 
and students should be encouraged to practice during the interludes between rounds. 
 
 
 Figure 21.  Students’ ability to assign the correct single letter abbreviation to a 
given structure improves after playing Amino Acid Hangman. 
 
Students’ ability to draw structures from memory was also improved for 17 amino 
acids after they played the Hangman game (Fig. 22).  Before the game, the majority of the 
class could only draw G, the simplest amino acid.  Afterwards, more than half the class 
could accurately draw the structures of G, A, V, L, I, P, S, and F.  Note that for 9 other 
amino acids, not one student drew the correct structure before the activity, but many 
students could properly draw these structures after the game.  Interestingly, no student 
attempted to draw N, Q nor R for either the pre- or post-test.  Perhaps this caution was due 
to the chance of losing extra credit.  In order to incentivize mastery of complicated 
structures, additional points could be assigned to certain side chains.  For each structure that 
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was attempted however, 5-65% more students were able to correctly sketch the amino acid 
after the activity than before playing Amino Acid Hangman.  The higher number of accurate 
responses indicates that students improved their ability and perhaps even their confidence to 
draw and recognize the standard amino acid structures.   
 
 
 Figure 22.  Students’ ability to draw the correct amino acid structure improves after 
playing Amino Acid Hangman. 
 
Students were enthusiastic to play when the game was presented as a means to extra 
credit while being a fun way to prepare them for relevant exam material.  Humor and fun 
contribute to active learning [17,18].  For example, students were advised that they could 
write a love letter in amino acid structures if they had a particular nerdy sweetheart, or they 
could write clandestine, encrypted messages.  Overall, we suggest that Amino Acid 
Hangman is a fun, educational, interactive exercise that improves students’ ability to draw 
and correctly assign the single letter code to amino acids. 
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V. Conclusions  
To me, it has been a privilege to work at the cutting edge of regenerative medicine, and I 
have been fortunate to occupy a specific, rare research niche during my six years in the 
Clegg Lab.  On the one hand, I have collaborated with efforts of the California Institute for 
Regenerative Medicine (CIRM) and have experienced the laser-focused drive to generate a 
product that restores vision to the blind.  On the other hand, I have also enjoyed the freedom 
to tinker with developmental mechanisms to radically expedite the derivation of potentially 
therapeutic cells.  For me, this dichotomy encompasses the main objective of my doctorate 
program, Biomolecular Science and Engineering. 
The work presented in this thesis primarily addresses two pertinent obstacles to the 
translation of stem cell therapies to the clinic.  The first pertains to the in vitro culture 
conditions of stem cells and their derivatives.  Currently, at the dawn of an upcoming era of 
treating human maladies with cellular therapies, it is acceptable to use xenogeneic reagents 
during production.   As the field matures however, the primary convention for generating 
these treatments is expected to utilize defined xeno-free culture conditions to obviate the risk 
of exposing patients to animal-derived immunogens. Here, I have demonstrated that a 
synthetic, good manufacturing practices (GMP)-compliant peptide copolymer supports the 
growth of H9 and H14 human embryonic stem cells (hESCs).  Due to the pluripotency of 
these cells, these findings can be applied to generate a wide range of therapeutic cell types.  
A second obstacle to bringing cell-based therapies bench-to-bedside is the cost and 
duration of in vitro cell culture.  I have assisted in developing a directed differentiation 
protocol that accelerates the derivation of hESC-RPE from several months to 14 days.  By 
replacing the xenogeneic substrate and many of the expensive recombinant growth factors, I 
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have taken the preliminary steps to adapt this rapid protocol to less expensive xeno-free 
conditions.  This directed differentiation procedure is expected to assist in the swift 
production of hESC-RPE as well as facilitate the study of RPE developmental mechanisms. 
Lastly, how could we hope for future innovative breakthroughs without keen scientists 
and doctors?  Educating the next generation of regenerative pioneers to approach problems 
with critical thought is essential for advancement.  Experiments and discoveries are not 
created by memorizing a textbook.  Therefore, we must provide undergraduate students with 
opportunities to practice critical thinking needed in a lab setting.  Engaging, interactive 
exercises encourage students to train their higher cognitive skills of analysis, synthesis, and 
evaluation.   And one should never underestimate the effects of having fun.  In teaching. In 
science.  In life.  
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Appendix 
A. Supplemental Tables 
Supplemental Table 1: Examples of hints and answers that can be used in Amino Acid 
Hangman.  Text in bold was used during the 4 rounds of Amino Acid Hangman described.  
Each letter is from the single letter code for amino acids developed by IUPAC and IUB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hint Written by Instructor Answer 
LET’S PLAY A GAME HANGMAN 
ALIENS FLY IN SPACESHIPS 
MEAN SHIPS PIRATES 
SCARY SNAKE VIPERS 
ANCIENT MEAT EATERS CAVEMEN 
AN INTERESTING CLASS CHEMISTRY 
TASTY GRAPES WINE 
SILLY MEMES INTERNET CATS 
TREES GIVE SHADE 
AFTER FALL WINTER 
AFTER WINTER SPRING 
WIND ANIMAL WEATHERVANE 
WILD ANIMAL TIGER 
IPAD APPLE DEVICE 
MARINE TV SHARK WEEK 
NICE PLANET EARTH 
MERRY CHRISTMAS REINDEER 
GAME CHEATER CARD SHARK 
W.M.D. IRAQ 
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B.  Supplemental Figures 
 
Supplemental Figure 1: Representative phase contrast images of H9 and H14 hESC colony 
morphology on Matrigel®, Synthemax®-R and Synthemax®II-SC during 7 passages.  
Images were taken 4-7 days post-seed.  Scale bar = 200µm 
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Supplemental Figure 2: Characterization of H14 hESCs maintained on Synthemax®II-SC 
(A) Representative flow cytometry histograms for pluripotency markers Oct4 and SSEA4 
from H14 cultures grown on the indicated substrate at passages 1, 3, 5 and 9.  (B) Relative 
mRNA expression of pluripotency genes in H14 cultures grown on Synthemax®II-SC, 
Synthemax®-R and Matrigel® at passages 1, 3, 5 and 9, as detected by qPCR.   (C) Relative 
mRNA expression of germ layer markers in H14 hESCs differentiated on Synthemax®II-SC 
as detected by qPCR.  (D) Normal karyotype of H14 hESCs maintained on Synthemax®II-
SC for 16 passages.  
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Supplemental Figure 3:  Characterization of H14 hESC-RPE derived on Synthemax®II-SC 
(A) Phase contrast and bright field images are shown of cells derived on different substrates. 
Mg-SR denotes the condition of hESCs grown and differentiated on Matrigel® then 
enriched as hESC-RPE on Synthemax®-R.  Scale bar = 200µm.  (B) Representative flow 
cytometry histograms are shown for the premelanosome pigmentation marker PMEL17 and 
the pluripotency marker Oct4 (not detected) for H14 hESC-RPE at passage 2, day 28 on the 
indicated substrate.  (C) Validation of the flow cytometry antibodies.  Oct4 antibody detects 
over 98% of the undifferentiated H9 positive control cells and 1.1% of Hs27 foreskin 
fibroblast negative control cells.  PMEL17 antibody detects over 99% of MEWO human 
melanoma positive control cells and 1.2% of Hs27 negative control cells. (D)  Normal 
karyotype of H14 hESC-RPE after spontaneous differentiation, enrichment and 3 passages 
on Synthemax®II-SC.  (E)  Quantification of ROS phagocytosis by H14 hESC-RPE derived 
on Synthemax®II-SC compared to H14 hESC-RPE derived on other substrates.  Fetal RPE 
(fRPE) were used as a positive control.   (F)  Quantification of ROS phagocytosis by H14 
hESC-RPE seeded onto surfaces coated with the defined substrates of Synthemax®II-SC or 
human vitronectin.  The function-blocking antibody to integrin αvβ5 significantly hinders 
phagocytosis in all hESC-RPE cultures, ** p < 0.01, ttest. 
 
 
 
Supplemental Figure 4:  Phase contrast and bright field images of lacunae in two hESC-
RPE cultures on Synthemax®II-SC.  (A) Lacunae in H9 hESC-RPE cultures on 
Synthemax®II-SC at passage 2 day 28. (B) Lacunae in H14 hESC-RPE cultures at passage 
1 day 28.  Scale bars = 200µm.  
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Supplemental Figure 5:  Gene expression in H9 and H14 hESC-RPE  (A) Expression of 
pigmentation and RPE marker genes in cells derived on the indicated substrate, as 
determined by qPCR. (B,C)  Gene expression of genes indicated in H9 hESC-RPE and H14 
hESC-RPE via PCR.  
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Supplemental Figure 6. The morphology of cells during differentiation and following 
enrichment. (A) 4X images of cells during differentiation. Scale bars = 500µm. (B) 10X  
images of cells during differentiation. Scale bars = 200µm. (C) Morphology of non-RPE 
cells enriched and culture under hESC conditions. Scale bar = 100µm. (D) Cells 21 days 
following enrichment on day 14 of differentiation with our without Y27632 during the first 
3 days post enrichment. Scale bars = 200µm. 
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Supplemental Figure 7: Reference sheet with the 20 standard amino acids at pH7. 
Structures were drawn with Accelrys Draw 4.1 freeware. 
 
